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Radiation therapy for patients with intact cervical cancer is frequently delivered using 
primary external beam radiation therapy (EBRT) followed by two fractions of intracavitary 
brachytherapy (ICBT). Although the tumor is the primary radiation target, controlling 
microscopic disease in the lymph nodes is just as critical to patient treatment outcome. In 
patients where gross lymphadenopathy is discovered, an extra EBRT boost course is 
delivered between the two ICBT fractions. Since the nodal boost is an addendum to primary 
EBRT and ICBT, the prescription and delivery must be performed considering previously 
delivered dose. This project aims to address the major issues of this complex process for the 
purpose of improving treatment accuracy while increasing dose sparing to the surrounding 
normal tissues. 
Because external beam boosts to involved lymph nodes are given prior to the 
completion of ICBT, assumptions must be made about dose to positive lymph nodes from 
 vi 
future implants. The first aim of this project was to quantify differences in nodal dose 
contribution between independent ICBT fractions. We retrospectively evaluated differences 
in the ICBT dose contribution to positive pelvic nodes for ten patients who had previously 
received external beam nodal boost. Our results indicate that the mean dose to the pelvic 
nodes differed by up to 1.9 Gy between independent ICBT fractions. 
The second aim is to develop and validate a volumetric method for summing dose of 
the normal tissues during prescription of nodal boost. The traditional method of dose 
summation uses the maximum point dose from each modality, which often only represents 
the worst case scenario. However, the worst case is often an exaggeration when highly 
conformal therapy methods such as intensity modulated radiation therapy (IMRT) are used. 
We used deformable image registration algorithms to volumetrically sum dose for the 
bladder and rectum and created a voxel-by-voxel validation method. The mean error in 
deformable image registration results of all voxels within the bladder and rectum were 5 and 
6 mm, respectively. 
Finally, the third aim explored the potential use of proton therapy to reduce normal 
tissue dose. A major physical advantage of protons over photons is that protons stop after 
delivering dose in the tumor. Although theoretically superior to photons, proton beams are 
more sensitive to uncertainties caused by interfractional anatomical variations, and must be 
accounted for during treatment planning to ensure complete target coverage. We have 
demonstrated a systematic approach to determine population-based anatomical margin 
requirements for proton therapy. The observed optimal treatment angles for common iliac 
nodes were 90° (left lateral) and 180° (posterior-anterior [PA]) with additional 0.8 cm and 
 vii 
0.9 cm margins, respectively. For external iliac nodes, lateral and PA beams required 
additional 0.4 cm and 0.9 cm margins, respectively. 
Through this project, we have provided radiation oncologists with additional 
information about potential differences in nodal dose between independent ICBT insertions 
and volumetric total dose distribution in the bladder and rectum. We have also determined 
the margins needed for safe delivery of proton therapy when delivering nodal boosts to 
patients with cervical cancer. 
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Chapter 1: Introduction 
1.1 RADIATION THERAPY FOR CANCER TREATMENT 
1.1.1 What is Radiation Therapy? 
Ever since x-rays were discovered by Wilhelm Conrad Röntgen in 1895, it did not 
take long for it to be adopted for both diagnostic and therapeutic uses. One of the first 
reported uses of radiation for therapeutic purposes was by an Austrian surgeon named 
Leopold Freund when he noted the disappearance of a mole following x-ray radiation in 1896 
(1). Although radiation therapy has advanced tremendously in the past century, the basic 
biological principles have remained the same; deliver sufficient ionizing radiation to 
malignant cells with the purpose of breaking enough chemical bonds in the malignant cell 
DNA to damage it and prevent cell division. However, the challenge in radiation therapy 
(RT) is that radiation does not differentiate between malignant and normal healthy cells. 
Therefore, advances in RT have been primarily in the direction of minimizing deposition of 
radiation to normal cells while maximizing radiation deposition to malignant cells. 
1.1.2 Planning and Delivery of Radiation Therapy 
Regardless of treatment modality and site, all radiation therapies contain three major 
components; simulation, planning, and delivery. For example, in external beam radiation 
therapy, patients are first simulated on a computed tomography (CT) scanner. This provides 
radiation oncologists volumetric information about location of disease and normal tissue. 
Also, the Hounsfield unit (HU) of voxels of a CT scan acquired from a calibrated CT scanner 
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can be converted to electron density, which gives treatment planning systems the capability 
of heterogeneous dose calculation (2). CT simulation is followed by treatment planning. 
Normal tissues and treatment targets are delineated by the radiation oncologist. Physicists or 
dosimetrists then generate treatment plans which satisfy the prescription criteria set by 
radiation oncologists while minimizing radiation to the normal tissues. Finally, after the plans 
are approved by the radiation oncologists, patients start receiving daily treatment at typically 
2 Gy per fraction delivered using a linear accelerator. 
One of the potentially major problems in the current RT process is that the simulation 
CT scan only represents a snapshot of the patient’s anatomy and the assumption that this 
represents the patient through the entire treatment is made. Since most radiation therapy 
courses last 6 – 7 weeks, the assumption that patient anatomy remains unchanged through the 
entire treatment is naïve. However, the effects of anatomical variation on target dose 
coverage have historically been minimal since beam configurations were simplistic and 
margins used were generous. With new technologies such as intensity modulated radiation 
therapy (IMRT), treatment plans have become more conformal, which leads to increased 
sensitivity to anatomical changes. 
Uncertainty caused by anatomical variation is just one of many uncertainties present 
in radiation therapy. As technologies become more advanced and more conformal delivery 
methods are developed, better understanding of uncertainties is essential to minimize the risk 
of underdosing the target. Although some uncertainties are universal, such as CT number and 
dose calculation, most uncertainties, including anatomical variations, are treatment site 
specific. This work focuses on uncertainties in the treatment of cervical cancer, especially in 
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the treatment of lymph nodal boost, with the hope of improving both the treatment planning 
and dose delivery process. 
1.2 BACKGROUND OF CERVICAL CANCER 
1.2.1 Statistics and Pathology  
The cervix is the area connecting the lower part of the uterus and upper vagina. 
According to the statistics collected by International Agency for Research on Cancer in 2008 
(3), cervical cancer is the third most common type of cancer in women worldwide. However, 
mortality rates of cervical cancer in the United States and other Western countries have 
reduced dramatically because of advanced screening techniques such as Pap smears. The 
National Cancer Institute estimates that there were12,170 new cases and 4,220 deaths in the 
United States in 2012 (4). Pathology of cervical cancer suggests that more than 75% of all 
cervical cancer cases are squamous cell carcinoma with the remaining composed of 
adenocarcinoma and undifferentiated neuroendocrine. 
1.2.2 Treatment Methods 
Surgery, chemotherapy, and radiation therapy may all be incorporated into treatment 
of cervical cancer. Cancer characteristics and side effects must be considered by the radiation 
oncologists when determining which treatment option best suits the patient. Clinical staging 
of invasive cervical cancer are classified using the internationally accepted International 
Federation of Gynecology and Obstetrics (FIGO) system (5). Originally created in 1938 with 
four major stage groupings, the system has undergone many revisions including the creation 
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of substages, which starting in 1994 distinguishes microinvasion (IA1 and IA2) and cervical 
diameter (IB). The system is unique because it is a clinical and not a surgical or radiographic 
staging system. Although it is not perfect, FIGO stages correlates with outcome when 
classification rules are strictly followed. 
Surgery can be most effectively used in early stage cervical cancer cases. In patients 
with stage IA1 disease, where the risk of extracervical involvement is low, type I simple 
extrafascial hysterectomy can be performed. Type II radical hysterectomy and pelvic lymph 
node dissection is generally recommended for stage IA2 and IB1 cervical cancers. For more 
advanced cancers, ultra-radical surgical procedures may be performed, although definitive 
chemoradiation is generally recommended in these cases. 
Radiation can be used to treat cervical cancer at all stages. Early stage cases such as 
IA1 and IA2 can be effectively treated with intracavitary brachytherapy alone for patients 
who are not operative candidates (6, 7). More advanced cases require external beam radiation 
therapy to treat the nodes as well. The debate between RT and surgery has been a heated 
topic with original research showing approximately equal 5 year survival rate of 80% for 
both treatment modalities (8). However, retrospective studies could be biased since younger 
patients in better health tend to opt for surgical methods because RT could potentially lead to 
loss of reproductive function and secondary cancers. On the other hand, one prospective 
study comparing RT to surgery showed equivalent disease control but a higher rate of grade 
2 to 3 complications in patients who received hysterectomy (9). In addition to being used 
alone, radiation therapy is often used in combination with surgery. Two recent prospective 
studies have shown the benefits of postoperative pelvic radiation therapy for patients with 
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intermediate risk features (10, 11). These randomized trials have shown a 46% reduction in 
risk of recurrence and statistically significant improvements in rate of death in patients 
receiving postoperative radiation. 
In the past 30 years, many researchers have investigated using either sequential or 
concurrent chemotherapy in combination with radiation therapy. Although initial results for 
neoadjuvant chemotherapy showed improved tumor response, they did not show improved 
survival rates (12-16). However, prospective trials published around the year 2000 showed 
significant improvement in overall survival, disease-free survival, and local control rates 
when cisplatin based chemotherapy was used concurrently with radiation therapy (11, 17-
20). For example, one of the studies has shown improved 5-year survival rates for patients 
with stage IB to IIB disease (79% versus 55%) (18). Because findings in those studies were 
so significant, the National Institute of Health made concurrent chemoradiation the standard 
of care for patients with locally advanced cervical cancer (21). 
1.2.3 Radiation Therapy of Cervical Cancer 
The goal of radiation therapy is to deliver sufficient dose to the target without 
exceeding normal tissue tolerance. However, in most cases of radiation therapy of cervical 
cancer, paracervical sites and regional lymph nodes are part of the treatment target area in 
addition to primary tumor. This makes the target irregularly shaped and conformal treatment 
planning very difficult. Because of greater than 3 cm interfractional internal organ motion 
(22), large treatment planning margins must be used to assure target coverage throughout 
entire treatment. However, using large margins often also means that normal tissues adjacent 
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to the target, such as bladder, rectum, sigmoid, and small bowels, are included in the 
treatment fields as well. Therefore, if dose is delivered using external beam RT alone, 
tolerance of normal tissues will be reached prior to the targets receiving the prescription dose 
(23-25). To maintain normal tissue dose below tolerance, intracavitary brachytherapy (ICBT) 
is normally given in conjunction with external beam RT. Brachytherapy treatments take full 
advantage of the inverse square law, delivering high doses to tissue closest to the source 
while sparing normal tissue beyond a few centimeters. 
External Beam Radiation Therapy 
There are two major functions of external beam radiation therapy (EBRT); to control 
microscopic disease and reduce size of primary tumor. EBRT treatment fields must cover the 
cervix, paracervical tissues which include the broad ligaments and uterosacral ligaments, and 
involved lymphatic nodes. The most common treatment field technique is using four fields 
(anterior-posterior [AP] and laterals). Traditionally, this was the best option because this field 
setup spared superficial tissue when low energy beams such as Co-60 sources and 6MV 
photons were used. Modern linear accelerators can generate greater than 15MV beams which 
makes a two field setup using only AP-PA beams also acceptable. Most radiation oncologists 
still prefer the traditional four field setup because studies have shown that using four beams 
instead of two can reduce dose to the small bowel and rectum (26). Four field box treatments 
are often also referred to as 3-dimentional conformal treatment (3D-CRT). Radiation 
oncologists are responsible for delineation of uterus, nodes, vagina, cervix, bladder, rectum, 
and margins for the fields. 
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In recent years, many institutions have explored the usage of IMRT for women with 
cervical cancer (27-35) with the hope of creating better conformal plans for normal tissue 
sparing. Unlike 3D-CRT, IMRT uses inverse planning techniques which automatically create 
a plan based on series of planner defined constraints. Planning studies so far have shown 
decreased bladder, rectum, small bowel, and even bone marrow dose without compromising 
target coverage when IMRT is used instead of 3D-CRT (28, 29, 32, 33). Prospective follow-
up studies comparing IMRT and 3D-CRT have also shown less acute and chronic 
gastrointestinal (GI) toxicity for patients receiving IMRT (27, 30, 31, 34). Another method of 
delivering intensity modulated radiation therapy is by using volumetric modulated arc 
therapy (VMAT) (36). Unlike traditional IMRT, which delivers dose in using predefined 
fixed angles, VMAT deliver dose using continuous gantry rotation and multileaf collimator 
motion with modulated dose rate. A planning study done by Cozzi et al. comparing IMRT to 
intensity modulated arc therapy with results showing improved homogeneity and 
conformality index with VMAT and decrease in rectum and bladder mean dose (37). 
Although all these results appear promising, the studies do not have enough patients and long 
follow-up duration to conclude that local control and survival rates are comparable to 
traditional 3D-CRT methods. Also, with the exception of the study by Van de Bunt et al. 
(35), which have shown anisotropic anatomical variation requiring treatment margin as large 
as 2.4 cm, none of the studies have analyzed anatomical variations during a RT course and its 
effect on conformal treatment methods. Because of uncertainties related to patient outcomes 
using conformal methods and large interfractional anatomical variations, most intact cervical 
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cancer patients receiving primary EBRT at The University of Texas MD Anderson Cancer 
Center are still treated with 3D-CRT.  
Intracavitary Brachytherapy 
ICBT is an integral part of radiation therapy for cervical cancer. Its primary function 
is to deliver boost dose to the gross tumor by using solid applicators which consists of a 
central tube called tandem and two lateral capsules, called ovoids. Figure 1 shows an 
example of the classic Fletcher-Suit-Delclos applicator system. There are three major reasons 
why the cervix is ideal for being irradiated using ICBT. First, radioactive sources can be 
placed in the center (in middle of cervix), above (inside the uterus), and below (inside the 
vagina) the tumor. Second, packing can be used in the vagina to push the bladder and rectum 
further away from the radioactive sources, which lowers the dose and toxicity to these 
organs. Finally, the uterus and vagina are relatively radioresistant and can tolerate doses as 
much as 90 Gy without developing radiation related complexities (38). Historically, ICBT 
was delivered using Radium-226 (226Ra), which has the average energy of 830 keV and half-
life of 1602 years. However, because of the high energy photon released (up to 2.45 MeV), 
226Ra sources require thick shielding. Also, since it is also an alpha emitter, it is extremely 
hazardous if the encapsulation holding the radium sulfate powder were to break. An 
alternative source to 226Ra is Cesium-137 (137Cs) which is a 662 keV gamma-ray emitting 
radioisotope with 30 year half-life. 137Cs is better than 226Ra because it requires less shielding 
and is also less hazardous. It overtook 226Ra as the most used source for ICBT in the mid 
1970s. Since the introduction of afterloading methods, Iradium-192 (192Ir) has become the 
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source of choice for ICBT. 192Ir has average energy of 380 keV and half-life of 74 days. The 
lower energy compared to 226Ra and 137Cs makes shielding more convenient and because it 
has high specific activity, it has enough activity for high-dose-rate treatments (described in 
more detail next paragraph). The only downside of using 192
 
Ir is its short half life. However, 
74 days is long compared to the average treatment time and dose rate decreases by less than 
2% during treatment. 
Figure 1: The Fletcher-Suit-Delclos applicator system which composes of a tandem and two 
ovoids. In the picture, one can see different ovoid sizes (mini to large) and 
tandems with varying angles (15° to 45°). Different combinations of tandem and 
ovoids can be used depending on patient specific anatomical features. 
Historically, low-dose-rate (LDR) ICBT was the preferred method of treatment 
because it offers greatest radiobiological advantages (39-44). It is a unique situation where 
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damage and repair occurs at the same time. When the dose rate is as low as 1 cGy/min (LDR 
dose rates are typically between 0.7 to 1 cGy/min), radiosensitivity of cells decrease and the 
curved shoulder portion of the cell survival curve becomes straighter. This effect is critical 
because as the survival curves become straighter, the survival percentage difference increases 
between normal tissues and tumor cells as dose is increased. Dose delivered using LDR has 
almost identical biological effect as dose delivered in 2 Gy per fraction using external beams. 
One of the downsides of LDR is in order to deliver enough dose to the target at low dose 
rates, long delivery times (typically 72 hours), has to be used. The patient must be 
hospitalized and immobile through the entire process, making it very uncomfortable and 
inconvenient. When ICBT was first performed, manual loading methods were used. The 
sources were preloaded into the applicator before it was inserted into the patient in the 
operating room. However, to reduce radiation to medical personnel, afterloading systems, 
where sources are manually or remotely loaded into the applicator after it has been inserted 
into the patient, were developed and used in the clinic. Afterloading systems also have the 
advantage of allowing dose distribution optimization based on patient anatomy and 
applicator location after insertion. 
In the past fifteen years, a new method of delivering ICBT, using high-dose-rate 
(HDR) sources (>1Gy/min), has gained popularity around the world (45-56). This technique 
uses a computer controlled remote afterloader to precisely move a single 192Ir source with 
activity greater than 10 Ci (3.7x1011 Bq) to different spots (dwell positions) in the applicator. 
With tremendous precision in timing and location, a single source can be used to replicate 
dose distribution of a LDR treatment. Also, when HDR planning is done using CT images, 
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the dose distribution can be inversely optimized like IMRT to create more conformal 
treatment plans with greater normal tissue sparing. The advantage of using HDR is that the 
entire treatment process takes only a few minutes instead of days. This leads to more 
convenience for patients and much less radiation exposure to medical personnel. The major 
disadvantage of HDR brachytherapy is that the radiation biology aspect is not well 
understood. The current method for calculating biological equivalent (BED) dose of HDR 
uses the identical linear-quadratic model as EBRT, which does not factor in typical 
brachytherapy BED calculation parameters, such as repair time and exposure duration. Also, 
there is no standard method for the delivery of dose using HDR. The dose per fraction and 
number of fractionations can vary significantly between institutions. The most common 
fractionation scheme in the United States is once per week using 6 Gy per fraction concurrent 
with primary EBRT. Literature comparing outcome results between HDR and LDR have 
showed equal survival rates between the two for small tumors but significantly lower 
survival rates for patients with stage IIIB disease when HDR is used (47, 49, 51, 52, 55). 
A third brachytherapy dose delivery method named pulsed-dose rate (PDR) 
irradiation can also be used for the delivery of ICBT. A 1 Ci (3.7x1010 Bq) 192Ir source is 
used instead of a 10 Ci (3.7x1011 Bq) source as in the HDR system. The source leaves the 
remote afterloading unit for approximately 15 min per hour to deliver a 50 to 70 cGy “pulse”. 
PDR is a great alternative to LDR and HDR because it has some of the advantages of HDR 
irradiation while having similar radiobiological effect as LDR treatments (57-59). For 
example, the lower dose rate reduces the room shielding requirements compared to HDR. 
Also, since the sources are not inside the patient at all times, nurses and visitors can avoid 
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exposure to radiation by entering the room when the source is in the safe. Finally, the 
applicators used for PDR are identical to LDR and HDR applicators, which facilitate use for 
individuals who have familiarity with such applicators. From all the advantages of using 
PDR as discussed above, it is the preferred method of delivering ICBT here at MD Anderson 
Cancer Center. 
The first guidelines for ICBT treatment planning were the Paris and Manchester 
methods (60). In an effort to standardize dose prescriptions and distribution, the International 
Commission on Radiation Units and Measurements (ICRU) released a report with 
recommendations on dose prescription and treatment techniques on ICBT in 1985 (61). 
Traditional points used in the Manchester system such as point A (the location where the 
uterine artery cross the ureter) and point B (location of obturator lymph nodes) were 
redefined. Additional points including bladder, rectal, and pelvic nodes were defined as well. 
Figure 2 shows the location of point A, B, bladder, and rectum. Nodal point definitions are 
explained in Section 1.2.4. 
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Figure 2: Locations of Point A, B, bladder and rectum as defined in ICRU 38. Point A is 
defined as the point 2 cm lateral to the central canal of the uterus and 2 cm up 
from the external os. Point B is defined as the point crossing the internal OS, 
parallel to the tilt of the pelvis, and 5 cm lateral from the midline. Bladder and 
rectum points can be identified on the lateral images. The bladder point is 
located on the most posterior surface point of the Foley balloon. The rectal point 
is located on a line drawn from the midpoint of the ovoids and 5 mm behind the 
posterior vaginal wall.  
In recent years, with advances in imaging technology, ICBT treatment planning using 
volumetric modalities such as CT and magnetic resonance imaging (MRI) have gained 
popularity. One of the advantages of using 3-dimentional images such as CT and MRI 
instead of radiographs is much better assessment of the dose delivered to target and critical 
organs, since organs are visible with varying tissue contrast. Volumetric imaging provides 
information about the tumor, which allows anatomy based dose optimization and inverse 
planning. Dose delivered to normal tissues such as bladder and rectum can also be 
determined more accurately. Studies comparing ICRU organ points, which represent 
maximum dose in theory, with actual dose hotspots (D2cc) determined using volumetric 
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images have shown varying discrepancy (62-64).  In response to the increasing popularity of 
using CT or MRI during the ICBT process, the gynecology group of the Groupe Européen de 
Curiethérapie-European Society for Therapeutic Radiation and Oncology (GEC-ESTRO) 
published a set of recommendations for target volume delineation and treatment planning 
using 3-dimentional based treatment planning (65). 
1.2.4 Boosting Radiation Dose to Positive Nodes 
Lymph node involvement is a very important predictor of patient treatment outcome. 
Studies have shown that survival rates for patients with positive para-aortic nodes are 
approximately half compared to patients without para-aortic involvement with similar disease 
stage (66-69). Therefore, it is important to detect nodes positive for metastasis and prescribe 
the appropriate treatment course for patients. There are many methods to detect lymph node 
involvement. The most sensitive method is surgical with either transperitoneal 
lymphadenectomy or laparoscopic lymph node dissection. Although sensitive, surgical 
methods are highly invasive and may cause severe complications (70). Non-invasive imaging 
techniques such as CT and MRI can also be used to evaluate lymph node involvement. Large 
nodes with diameter greater than 1 to 1.5 cm could potentially suggest disease metastases but 
using nodal size alone can result in false positives since inflammation could also cause nodal 
enlargement. On the contrary, 18F-fluorodeoxyglucose positron emission tomography (FDG-
PET) imaging, which measures metabolic activity, is very useful for detecting disease 
metastasis in the lymph nodes, with a sensitivity of 82% and specificity of 95% reported in 
literature (71-75). Kidd et al. found that using FDG-PET imaging for positive node detection 
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is comparable to historical data and correlates to patient recurrence and survival outcomes 
(76). Their results showed significant correlation between PET detected positive lymph 
nodes and prognosis (Fig. 3). 
 
Figure 3: Kaplan-Meier disease-specific survival probability curves separated by (A) FIGO 
staging and (B) PET detected nodal involvement. (Kidd, E et al: J Clin Oncol 
Vol. 28, 2010: 2108-13. Reprinted with permission. © 2010 American Society 
of Clinical Oncology. All rights reserved.) 
Although nodal involvement from cervical cancer may occur anywhere along the 
lymphatic drainage pathway, cervical cancer most commonly spreads to the external iliac 
nodes and common iliac nodes with lower percentage of spread further away from the 
primary site (77, 78). Typically, 45 to 50 Gy is adequate to control microscopic disease in the 
lymph nodes and delivered as part of the primary EBRT. Guidelines for delineation and field 
setup can be found in ICRU Report 38 (61). When nodal involvement is only in the pelvic 
region, nodes are included in the primary fields treating the central disease. Four-field 3D-
CRT setup is used for extended para-aortic fields to reduce dose to small bowel and kidneys. 
In addition, recent studies have shown advantages of using IMRT for extended fields to 
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further reduce toxicity (32, 34). An example of an extended field EBRT treatment plan with 
all nodal regions treated can be seen in Figure 4. 
 
Figure 4: Example of extended field EBRT which includes primary disease, pelvic nodes, 
and para-aortic nodes. Two four-field 3D-CRT sets of beams matching at L5 
were used. 
In patients where gross lymphadenopathy is discovered, nodal regions are typically 
boosted to a total dose of 60 to 66 Gy (79). Prescribing dose for nodal boost is not straight 
forward. Although radiation oncologists know how much total dose the nodal region needs to 
receive, they must take into account dose contributions to the nodes from primary EBRT and 
ICBT. Determining dose contribution from primary EBRT is simple. Since it is part of the 
treatment planning target, the nodes receive full prescription homogeneous dose. Nodal dose 
contribution from ICBT is slightly more difficult to determine. When 2-dimentional 
radiographs are used for treatment planning, nodal structures cannot be seen since soft tissue 
contrast on x-ray films is minimal. Therefore, bony structures are used to estimate nodal 
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locations and dose. ICRU Report 38 recommends using the reference points on the lymphatic 
trapezoid of Fletcher, shown in Figure 5. When CT or MRI images are used for ICBT 
planning, positive nodal structures can be seen and delineated by radiation oncologists. The 
nodal dose contribution from ICBT is commonly described by taking the mean nodal dose of 
the entire volume. Because studies have shown strong correlation between longer treatment 
time and decrease in disease control (80-82), the optimal time to deliver nodal dose boost is 
during the two weeks of ICBT to prevent elongation of overall treatment duration. However, 
since nodal boosts are given prior to the second ICBT fraction, radiation oncologists must 
make the assumption that both ICBT fractions contribute equal dose to the nodes. Therefore, 
the equation used to calculate boost dose to positive nodes is: 
𝐸𝑥𝑡𝑒𝑟𝑛𝑎𝑙 𝑁𝑜𝑑𝑎𝑙 𝐵𝑜𝑜𝑠𝑡 =  𝑇𝑜𝑡𝑎𝑙 𝐷𝑜𝑠𝑒 − 𝑃𝑟𝑖𝑚𝑎𝑟𝑦 𝐸𝐵𝑅𝑇 − (𝐼𝐶𝐵𝑇1 × 2)  
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Figure 5: The lymphatic trapezoid of Fletcher as defined by ICRU Report 38 (61). Shows the 
method to determining external iliac, common iliac, and para-aortic nodal dose 
from x-ray films. The nodal points are based on bony locations since there is no 
soft tissue contrast on radiographs. 
Pelvic nodal boost are normally boosted with small AP-PA opposing fields. Using 
such field setup allows the avoidance of bladder and rectum, and reduce the risk of ureteral 
stricture (83). However, any small bowel in the field will receive the full prescribed dose, as 
seen in Figure 6b. For the common iliac and para-aortic nodes, multifield 3D-CRT or IMRT 
is normally used to spare the anterior small bowel. Example of a para-aortic nodal boost is 
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shown in Figure 6a.
 
Figure 6: Example of beam setup and dose distribution for a patient receiving nodal boost in 
both para-aortic (A) and external iliac (B) nodal regions. Para-aortic nodes were 
planed and treated with 8-field IMRT while external iliac nodes are treated with 
two field AP-PA beams. 
1.3 CURRENT OBSTACLES (AND POSSIBLE SOLUTIONS) IN HIGH PRECISION RADIATION 
THERAPY OF CERVICAL CANCER 
1.3.1 Motivation for this Project 
Cervical cancer is one of the few anatomical sites where radiation therapy combines 
multiple courses from different modalities for curative intent. As Section 1.2.3 has shown, 
this is a complex process requiring external beam radiation therapy and brachytherapy to 
strongly complement each other. Although most researchers have focused on improving 
primary EBRT and ICBT, one aspect of cervical cancer treatment that has not been a focus of 
research is external beam nodal boost. As discussed in Section 1.2.4, disease detection and 
treatment in the nodal regions is extremely crucial to patients’ survival probabilities. Even 
though not all patients require nodal boosts, the number of patients requiring nodal boost is 
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not negligible. Out of the 95 intact cervical cancer patients treated with primary EBRT and 
ICBT at MD Anderson in 2011, 46 (51%) received external beam boost to at least one nodal 
region. The motivation behind this project is to seek areas of potential improvement in 
boosting dose to lymph nodes and provide solutions.  
1.3.2 Difficulty in Prescribing Nodal Boost 
Because nodal boost dose is delivered prior to the second ICBT fraction, radiation 
oncologists must make assumptions about the second ICBT fraction prior to nodal boost dose 
prescription. In current practice, radiation oncologists assume that the first and second ICBT 
fractions contribute equal dose to the pelvic nodes. However, this assumption might not be 
accurate because the purpose of ICBT is to treat the primary tumor. Independent insertions of 
applicators can have many variations; tandem length and rotation, ovoid sizes, applicator 
locations in the pelvic, and dose distributions are just a few of the examples. In most 
situations, radiation oncologists make the attempt to remain as consistent as possible between 
the two ICBT fractions. In practice, this is difficult because patient anatomy could change 
dramatically between the two insertions. In cases where radiation oncologists suspect the 
nodal dose contribution from the second fraction will be lower, often due to shrinkage of 
primary tumor, conservative prescriptions methods are used for nodal boost to prevent under-
dosage. Such practice makes nodal dose prescription subjective and highly dependent on 
radiation oncologist experience. However, if variations in nodal dose between independent 
ICBT insertions are analyzed in an unbiased patient population, variations can be quantified 
and provide radiation oncologist with extra information when prescribing nodal boost dose. 
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Another difficulty in nodal boost dose prescription is caused by the increasing use of 
more conformal radiation therapy methods. Organ dose distributions from whole pelvis 
IMRT and inverse planning of ICBT are vastly different from 3D-CRT and brachytherapy 
dose distributions. Traditionally, understanding the total dose received by the normal organs 
such as bladder and rectum has been simple. During primary EBRT, the bladder and rectum 
essentially receive full prescription dose. During ICBT, bladder and rectum dose hotspots can 
be estimated using ICRU bladder and rectum points. Therefore, maximum dose to each organ 
can be estimated by summing the prescription EBRT dose and ICRU point dose from ICBT.  
Bladder and rectum dose distributions from conformal radiation therapy methods are much 
more heterogeneous. For example, hotpots and coldspots from inverse planned IMRT are 
much less predictable because of the large number of beams and leaf segments. Therefore, 
using traditional methods to quantify dose received by normal tissues may lead to 
inaccuracies. Since the hotspots from EBRT and ICBT might not be at the same location, 
traditional dose summation methods only represent the worst case scenario. One solution to 
this problem is by using deformable image registration (DIR) methods, which has the 
capability to locate locations of matching voxels on different images. Using DIR, dose 
summation can be performed volumetrically since the images are matched voxel-by-voxel. 
Better understanding of total normal tissue dose such as bladder and rectum is very important 
in prescribing nodal boost. Since normal tissue dose tolerances could be the limiting factors 
in nodal boost prescription, higher dose could potentially be prescribed when the actual 3D 
dose distributions are viewed instead of just the worst case scenario. 
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1.3.3 Rethinking How Nodal Boost Dose is Delivered 
Currently, external radiation nodal boosts are delivered using photons. Since photon 
beams are attenuated exponentially after the build-up region, all tissues along the beam path 
receive some radiation. Therefore, regardless of the beam configuration, some normal tissue 
will receive a large amount of prescription dose. For example, although the bladder and 
rectum are avoided during external iliac nodal boost, as shown in Figure 6b, the small bowel 
receive essentially the full prescribed dose. An alternative method of delivering dose is by 
using protons. In proton therapy, the beam has finite range and delivers almost all of its 
energy at the end of its range (termed the Bragg peak). Clinically, this feature of protons is 
extremely advantageous because all organs beyond the distal edge of the beam can be spared. 
Contrary to photons, a single PA proton beam can be used to deliver conformal dose to 
external iliac nodes. Small bowel will be spared because it lies beyond the distal margin. 
However, the advantages of proton therapy are not without a cost. Proton beams are 
extremely sensitive to changes in the beam path. Uncertainty related to anatomical changes 
need to be considered thoroughly in order to use proton therapy to target the boost volume. 
Dosimetric differences caused by interfractional anatomical variations are magnified in nodal 
boosts because a very small target is irradiated over a small number of fractions. Variations 
in anatomy in the beam path can cause the proton beam edge to shift off the target, resulting 
in under-coverage in either the distal or proximal end of the target. In order for protons to be 
used in the clinic, adequate distal and proximal margins must be used during proton nodal 
boost planning to account for anatomical uncertainties. 
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1.4 ABOUT DISSERTATION 
1.4.1 Purpose and Hypothesis 
The purpose of this project is to improve external beam radiation therapy of 
lymphatic nodal boost during a course of cervical cancer treatment by: 1) Quantifying 
interfractional uncertainties. 2) Developing and validating dose accumulation tools between 
external beam radiation therapy and brachytherapy. 3) Exploring alternative treatment 
modalities. 
The hypothesis of this project is separated into three parts. First, rigid 2D-3D image 
alignment between films and CT images can be used to quantify nodal dose differences from 
independent ICBT insertions. Second, deformable image registration can be used to sum 
normal tissue dose from EBRT and ICBT. Third, ray-tracing methods can be used to 
determine interfractional anatomical variation margin requirements for proton therapy of 
nodal boost. 
1.4.2 Specific Aims 
There are three specific aims to this project, which are used to address the purpose 
and validate the hypothesis. The aims are listed below: 
1. Quantify variations in pelvic nodal dose due to applicator placement during a 
multi-fraction ICBT course. 
2. Develop and validate deformable image registration methods for the use of 
volumetric summation of bladder and rectum dose from ICBT to an external 
beam planning CT image set. 
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3. Calculate nodal boost planning margins needed for proton therapy to account 
for interfractional anatomical variations. 
1.4.3 Organization of Dissertation 
This dissertation is separated into five chapters. The first chapter is used to provide 
the necessary background information to the issues and problems that are being tackled in 
this project. The next three chapters provide details on the methods used to address each 
specific aim and their respective results. Extra background relating to the tools and method in 
each specific aim are provided in the middle chapters as well. The final chapter is where all 
the results are brought together. It is where we look at the big picture and anticipate the 
impact of the findings in this project, discuss how results can be implemented in clinical 
practice, and identify future work that could be done to improve upon current findings. 
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Chapter 2: Variability in Pelvic Nodal Dose between Independent 
Intracavitary Brachytherapy Fractions for Treatment of Cervical Cancer 
2.1 SPECIFIC AIM 1 
Quantify variations in pelvic nodal dose due to applicator placement during a multi-
fraction ICBT course. 
2.2 INTRODUCTION 
In patients with involved lymph nodes, which are often identified by PET and/or 
biopsy, additional radiation following primary pelvic radiation therapy is delivered to bring 
the total lymph node dose to 60 – 66 Gy range (79). Because brachytherapy can contribute a 
significant dose to pelvic lymph nodes, it needs to be taken into account when determining 
the appropriate final boost dose. At MD Anderson, the external beam boost to involved 
lymph nodes is given before the completion of ICBT. Therefore, assumptions about the boost 
to positive lymph nodes for future implants are made to determine the lymph node boost 
dose.  
As discussed in Section 1.3.2, in current practice, radiation oncologists assume that 
the first and second ICBT fractions contribute equal doses to the pelvic nodes. However, this 
assumption might not be accurate since independent insertions of applicators can vary with 
respect to many factors: tandem length and rotation, ovoid size, applicator location in the 
pelvis, and dose distributions (84-86), which may all contribute to the variation in node 
doses. The purpose of this specific aim was to quantify differences in nodal dose between 
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independent ICBT fractions due to applicator placement between ICBT fractions. 
Correlations between dose variations and external factors such as tandem angle rotation and 
applicator system placement were evaluated as well. 
2.3 METHODS AND MATERIALS 
2.3.1 Patient Cohort 
The MD Anderson Cancer Center Institutional Review Board approved this 
retrospective study. Ten patients with intact cervical cancer and positive nodes which 
required nodal boost were selected for this study. The patients had clinical stage IIA to IIB 
cervical cancer and were treated between August 2008 and December 2010. All patients 
received primary EBRT delivered in 1.8-Gy fractions to a total dose of 45 Gy. Two fractions 
of PDR ICBT were delivered immediately after EBRT at approximately 20-Gy per fraction 
prescribed to Point A. Delivery duration for each ICBT fraction was 44 hours, and the two 
fractions were spaced 2 weeks apart. ICBT was delivered using Fletcher-Suit-Delclos tandem 
and ovoid applicators with ovoid sizes ranging from small (20-mm dia.) to medium (25-mm 
dia.). ICBT planning was performed using orthogonal radiographic films obtained after 
applicator insertion in the operating room. All patients also had PET-positive pelvic nodes 
that were treated with a boost to a mean total dose of 62.1 Gy (range 60 Gy – 66 Gy). All 
patients underwent two CT simulations, one before primary EBRT and one before delivery of 
the nodal boost. Positive nodes were delineated on the CT scans by the radiation oncologist. 
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2.3.2 Aligning ICBT Film Images and 3D Dose to EBRT CT Image Sets 
Since CT images at the time of ICBT were not available for all patients, we had to 
devise a method to determine spatial correlation between film and CT images and then 
transfer the ICBT dose from the film images to the CT images. Figure 7 provides a schematic 
of the methodology that was used; the details of which are presented below. Original ICBT 
planning for all patients was performed by dosimetrists and approved by radiation 
oncologists. AP and lateral films used for planning were obtained in the operating room 
immediately after applicator insertion. In this work, original clinical plans were done in the 
Plato treatment planning system (TPS) v. 14.3.7 (Nucletron, Netherlands) and replicated 
using the Oncentra TPS v. 4.0 (Nucletron, Netherlands) with dwell positions identical to 
those in the original clinical plans. Dwell times on the replicated plans were adjusted to 
account for differences in the activity of the current radioactive source and the activity of the 
source used at the time of treatment. Dose calculations were performed using guidelines 
provided by the American Association of Physicists in Medicine Radiation Therapy 
Committee Task Group #43 (87, 88). Unlike its predecessor, Plato, the Oncentra TPS allows 
calculation of the dose in three-dimensional space, which we calculated using a dose grid of 
30 x 30 x 40 cm3 with a voxel size of 2 x 2 x 2 mm3 centered at the internal os. International 
Commission on Radiation Units and Measurements (ICRU) point A (left+right), as defined 
in Section 1.2.3, was placed on the replicated plans as a method to verify the accuracy of the 
replication process. The plans were then exported as DICOM files, which contained DICOM 
images of the AP and lateral films along with the DICOM-dose file. Since each patient had 
two ICBT fractions, 20 replica treatment plans were done.  
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Figure 7: Schematic of the procedure to determine differences in nodal dose between 
independent intracavitary brachytherapy (ICBT) fractions. First, films from 
ICBT fractions 1 and 2 (ICBT 1 and ICBT 2) were aligned to the computed 
tomography (CT) image set from treatment simulation (sim) performed before 
delivery of the nodal boost. Specifically, the original ICBT clinical plans were 
replicated using an Oncentra treatment planning system with dwell positions 
identical to those in the original clinical plans, and dose calculations were 
performed using guidelines provided by the American Association of Physicists 
in Medicine Radiation Therapy Committee Task Group 43 (87, 88). To permit 
alignment of ICBT film images to CT images, digitally reconstructed 
radiographs (DRRs) were generated from CT images in the anterior-posterior 
(AP) and lateral (Lat) directions. The replicated ICBT films and the DRRs were 
then aligned using a published algorithm (89). The alignment result was used to 
shift the ICBT dose into the CT coordinate system to obtain shifted doses for 
the first and second ICBT fractions, and these doses were imported into a 
Pinnacle (PINN) treatment planning system. Finally, differences in dose were 
analyzed volumetrically. 
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Because we are aware of no commercial tools that can align two-dimensional film 
images to three-dimensional CT image sets and can transfer dose from film plans to CT 
images, in-house software using MATLAB v. 7.12.0 (The MathWorks, Inc, Natick, MA) was 
generated to achieve the desired task. To align ICBT film images to external beam planning 
CT images, digitally reconstructed radiographs (DRRs) were first generated from CT images 
in the AP and lateral directions. These DRRs were then exported and aligned with their 
respective film counterparts. This is possible because although film images are two-
dimensional, orthogonal films with a common reference point can provide three-dimensional 
information. Aligning two sets of orthogonal two-dimensional radiographs can provide 
offsets in the x, y, and z directions. 
To align the ICBT films and DRRs, rectangular regions with identical dimensions 
encompassing the nodal region of interest and surrounding bony anatomy were first drawn on 
both the films and DRR image sets to localize the area used for alignment. Global image 
registration was not used because it is more critical to align the region closest to the nodes 
correctly than to have the entire pelvic and lumbar region aligned reasonably well. Because 
contrast on radiographs is greatest between bone and soft tissue, pelvic and lumbar bony 
anatomy within the rectangular regions delineated on the films and DRR image sets were 
aligned automatically using cross-correlation algorithm developed by Guizar-Sicairos et al. 
(89) and modified for this project. The algorithm uses rigid image registration that allows 
three degrees of freedom: translation in the AP, SI, and RL axes. Some of the modifications 
such as two secondary checks of alignment accuracy were also developed to facilitate use of 
the software. The first displays graticules centered at the isocenter on both film and DRR 
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images. The second overlays film and DRR images and displays each using 50% visibility or 
a checkerboard of alternating images. When auto-alignment results were inadequate or 
appeared incorrect, because of either bad image quality or lack of information, secondary 
alignment methods were used and results were adjusted manually. Manual alignment also 
allowed for rotations, i.e., pitch, yaw, and roll, of the film images to provide more accurate 
alignment. An example screen capture of the graphical user interface of the in-house software 
is shown in Figure 8. 
 
Figure 8: User interface created in-house using MATLAB for aligning digitally reconstructed 
radiographs (DRRs) and film images. Auto-alignment results can be verified 
manually by using the graticules and fusion display. 
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To validate the accuracy of our automatic image registration algorithm, a reference 
DRR image set and eight shifted DRR image sets with known shifts were created from a 
single CT image set, as shown in Figure 9. The shifted DRR image sets were created by 
shifting the reference DRR isocenter ±2 cm, ±3 cm, and ±4 cm in the RL, AP, and SI 
directions, respectively. Large shifts were chosen to test the robustness of the alignment 
method. Using our alignment software, shifted DRRs were treated as simulated ICBT film 
images and aligned to the reference DRR images. Without any manual intervention, the shifts 
calculated by the alignment software were compared to the known shifts of the isocenters. 
Differences in shifts were recorded. 
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Figure 9: Reference DRR and 4 out of the 8 shifted DRRs used for validation testing of our 
rigid alignment algorithm. Only shifts in the LR and SI direction are shown in 
figure. 
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To link the ICBT three-dimensional dose to external beam planning CT images, we 
needed to know the spatial association between the ICBT dose grid, film images, and 
external beam planning CT images. The center of the ICBT dose grid is also the planning 
isocenter, which was defined at the internal os during treatment planning. Prior to image 
registration, the ICBT film images were cropped so that the internal os was at the center of 
the image, which made the center of the images and the dose grid identical. Differences in 
film and DRR isocenter, obtained from our image registration software, were then used to 
calculate the location of the film isocenter on the CT image set. Once we identified the 
location of the film isocenter on the CT image sets, the exported DICOM-dose files from 
Oncentra were converted to Pinnacle (Philips Medical Systems, Andover, MA) dose format, 
rotated and shifted to the correct isocenter location, and imported into Pinnacle using in-
house-developed software tools. 
2.3.3 Analyzing Nodal Dose Differences between Independent ICBT Fractions 
The Pinnacle TPS is limited in dose-manipulation such as voxel-by-voxel dose 
accumulation and cumulative dose-volume histogram analysis. Therefore, to analyze 
differences in nodal dose between two independent ICBT fractions, a three-dimensional 
binary mask of all the positive nodes and their doses was exported from Pinnacle to be 
analyzed using another in-house MATLAB program. Since dose and CT voxel sizes are not 
the same, dose grids were then resampled to obtain the same resolution as the CT image set. 
With the binary mask and dose having an identical resolution, we were able to extract dose 
within the structures of interest to be evaluated or manipulated. Differences in nodal dose 
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contribution between the first (ICBT1) and second (ICBT2) insertions in terms of mean dose 
and D90
Calculating differences in nodal dose between independent ICBT fractions does not 
explain the source of the variations. We wanted to quantify and correlate factors that cause 
these dose differences. To eliminate differences caused by dose prescription, we calculated 
the ratio between the average ICRU point-A doses from the first and second ICBT fractions 
and multiplied the dose from the second ICBT fraction by this ratio. This normalized the 
dose of the second fraction, such that its dose prescription was identical to that of the first 
fraction. After dose normalization, tandem angle and length variations and system location 
shifts were analyzed. Tandem angle variations were determined by measuring the separation 
in angle between the tandem and midline of the pelvis, as shown in Figure 10. Tandem length 
variations were calculated by measuring the length of tandem from the tip to the internal os. 
System location variations were determined by comparing the differences in internal os 
location within the pelvis on the CT image set between the first and second ICBT fractions in 
RL, AP, and SI directions. The total magnitude of system location shift was calculated by 
taking the root of the sum of squares in the three directions. Figure 11 shows differences in 
isocenter location between the two ICBT fractions. Two-tailed Spearman’s rho correlation 
tests were used to determine whether correlations existed between tandem angle, system 
location, and variations in nodal dose. 
 (the dose received by at least 90% of the volume) were calculated. 
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Figure 10: Tandem angle (θ) was determined by measuring the separation in angle between 
the tandem and midline of the pelvis. 
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Figure 11: Differences in system shifts between the first and second intracavitary 
brachytherapy fractions. Variation was smallest in the lateral direction, while 
most variation occurred in the anterior-posterior direction. Most shifts between 
the first and second fractions were in the anterior and inferior direction. Box 
graphs show 25th percentile, median, 75th percentile, and outliers for variations 
in each axis. 
2.4 RESULTS 
2.4.1 Validation of Image Registration Algorithm 
Validation results of the automatic image registration algorithm used in this study is 
shown in Table 1. The mean discrepancies between the calculated and known shifts were 
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0.78 mm, 0.8 mm, and 1.14 mm in the RL, AP, and SI directions, respectively. Maximum 
discrepancies between the calculated and known shifts were 1.25 mm, 1.88 mm, and 2.5 mm 
in the RL, AP, and SI directions, respectively. 
Table 1: Results for auto-alignment algorithm. A reference DRR image set was first 
generated using isocenter near the center of the pelvis. Shifted-DRR image set 
were generated by shifting the isocenter ±2 cm, ±3 cm, ±4 cm in the LR, AP, 
and SI directions, respectively. 
 
Difference (mm) 
Shifted-DRR image 
set (isocenter shift) RL AP SI 
2 cm left 
3 cm anterior 
4 cm inferior 
1.25 1.88 2.11 
2 cm left 
3 cm anterior 
4 cm superior 
1.25 1.09 1.33 
2 cm left 
3 cm posterior 
4 cm inferior 
0.31 0.47 2.50 
2 cm left 
3 cm posterior 
4 cm superior 
0.31 0.47 0.16 
2 cm right 
3 cm anterior 
4 cm inferior 
1.25 0.47 0.94 
2 cm right 
3 cm anterior 
4 cm superior 
1.25 0.47 1.72 
2 cm right 
3 cm posterior 
4 cm inferior 
0.31 0.47 0.23 
2 cm right 
3 cm posterior 
4 cm superior 
0.31 1.09 0.16 
    Mean 0.78 0.80 1.14 
Max 1.25 1.88 2.50 
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2.4.2 Nodal Dose Differences from Independent ICBT Fractions 
For analysis of differences in patient nodal dose between the first and second ICBT 
fractions, nodes were divided into two regions, distal pelvic and proximal pelvic, with respect 
to location of central disease. The distal pelvic region included common iliac lymph nodes, 
and the proximal pelvic region contained external, internal, and obturator lymph nodes. Of 
the 10 patients, 6 had PET-positive distal and proximal pelvic nodes, 3 had PET-positive 
proximal pelvic nodes only, and 1 had PET-positive distal pelvic nodes only. All nine 
patients with positive proximal pelvic nodes had bilateral positive nodes. Of the seven 
patients with positive distal pelvic nodes, five had multiple positive distal pelvic nodes, and 
two had a single positive distal pelvic node. Together, the 10 patients in the study had 20 
positive proximal pelvic nodes and 14 positive distal pelvic nodes. Approximate locations of 
all nodal centroids, or geometric center, as calculated by Pinnacle TPS are show in Figure 12. 
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Figure 12: Approximate centroid locations of all analyzed nodes for all patients displayed on 
an atlas computed tomography image. The blue and green spheres represent 
nodes in the distal and proximal pelvic regions, respectively. 
Differences in nodal dose contributions between the ICBT1 and the ICBT2 are shown 
in Figure 13. Positive and negative nodal dose differences between the two ICBT fractions 
means higher and lower ICBT dose from the second fraction, respectively. For the proximal 
and distal pelvic nodal regions, the mean±1SD (range) differences between the ICBT1 and 
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ICBT2 mean nodal dose were 8.6±85.1 (-134.5 to 192.8) cGy and -46.8±55.3 (-172.7 to 
20.0) cGy, respectively. The 10th-percentile, 90th-percentile, and median differences 
between ICBT1 and ICBT2 mean nodal dose were -92.8 cGy, 134.1 cGy, and 8.9 cGy, 
respectively, in the proximal pelvic region and -143.4 cGy, 14.1 cGy, and -18.86 cGy, 
respectively, in the distal pelvic region. Mean differences between ICBT1 and ICBT2 D90 for 
proximal and distal pelvic nodal regions were 5.2±69.8 (-110.6 to 145.2) cGy and -21.9±38.4 
(-84.6 to 46.9) cGy, respectively. The 10th-percentile, 90th-percentile, and median 
differences between ICBT1 and ICBT2 D90 were -82.4 cGy, 109.1 cGy, and 0.9 cGy, 
respectively, in the proximal pelvic region and -83.9 cGy, 30.3 cGy, and -10.5 cGy, 
respectively, in the distal pelvic region. 
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Figure 13: Differences between the expected and delivered nodal dose from intracavitary 
brachytherapy for the proximal and distal pelvic regions. Box graphs show 25th 
percentile, median, 75th percentile, and outliers for both the mean nodal dose 
and the dose received by at least 90% of the nodal volume (D90). 
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2.4.3 Correlation between Tandem and Applicator Location Variations and Nodal Dose 
Difference 
Two-tailed Spearman’s rho correlation tests were performed between tandem angle 
and length variations, applicator system location variations in the RL, AP, SI directions, total 
magnitude of applicator system shift, and normalized nodal dose differences from 
independent ICBT fractions. Proximal pelvic node dose was affected by AP and lateral shifts 
in applicator placement. Distal pelvic nodes were impacted by tandem angle and total 
magnitude of applicator shift. Also, with the exception of one node, anterior shifts increased 
pelvic node doses, while posterior shifts decreased node doses. Plots for all significant pairs 
are shown in Figure 14. 
  
 43 
 
Figure 14: Graphs of normalized dose differences for pelvic nodes between the first and 
second intracavitary brachytherapy (ICBT) fractions versus applicator changes 
between the first and second ICBT fractions for relationships with significant 
correlations (p<0.05). 
2.5 DISCUSSION 
To the best of our knowledge, difference in pelvic nodal dose from different ICBT 
fractions has not been explored previously. Results from this work show that the absolute 
difference in mean node dose from independent implants can be as high as 1.9 Gy and 1.7 Gy 
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in proximal and distal pelvic nodes, respectively. However, only 20 percent of proximal and 
21 percent of distal mean nodal dose absolute differences were greater than 1 Gy. 
To achieve this study objective, we developed an in-house software with the capacity 
to utilize exported DICOM images and dose files from the Oncentra TPS, align the two-
dimensional film images with CT image sets from EBRT, and import corrected 
brachytherapy dose onto the CT image. The results from validation of our auto-alignment 
algorithm showed that on average, the registration error was small. In the RL and AP 
directions, the average difference was less than 1 mm, while it was slightly more than 1 mm 
in the SI direction. The worst registration errors in the RL, AP, and SI directions were 1.25 
mm, 1.88 mm, and 2.50 mm, respectively. This is not surprising because registration 
accuracies are highly dependent on image resolution and the CT image set used for testing 
had 1.2-mm resolution in the RL and AP directions and 2.5-mm resolution in the SI 
direction. Therefore, in the worst-case scenario, differences resulted from misalignments is 
approximately 1 pixel. Also, although the DRRs were generated from the same CT image set, 
there are still differences because shifting isocenter and regenerating DRR images is not 
equivalent to shifting the center and cropping the reference DRR images. DRRs are 
generated by projecting a point source through the CT image. By shifting the isocenter, we 
essentially shifted the point source and generated new images from the new reference point. 
Therefore, regenerated DRR images are not identical, especially for pixels that are further 
from the isocenter. 
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2.5.1 Nodal Dose Variations in the Proximal Pelvic Region 
In the proximal pelvic region, the mean difference between the ICRT1 and ICRT2 
mean nodal dose was 8.6 cGy, such difference is negligible. This indicates equal probability 
for the second ICBT fraction to contribute lesser or greater dose than the first ICBT fraction. 
However, the 1SD in dose difference for proximal pelvic nodes was almost 1 Gy with 
maximum absolute difference being 1.93 Gy. Spearman’s rho two-tailed tests indicated that 
the difference in proximal pelvic nodal dose was significantly correlated with shifts in the 
applicator system in the RL and AP directions (p<0.05). This is not unexpected because dose 
distribution directly follows the applicator placement and any shifts in the axial plane would 
move the distribution either closer to or further from the nodal region of interest. Figure 14a 
shows that in general, the contribution to nodal dose from the second ICBT fraction 
increased when the applicator system moved anteriorly and decreased when the applicator 
system moved posteriorly. This occurred because applicator placement is normally posterior 
to the proximal pelvic nodes and if the applicator is moved more anteriorly, the higher-dose 
region will be closer to the nodes and cause an increase in nodal dose. Figure 14b shows that 
in general, when the applicator system was shifted laterally, dose to the nodes on the side of 
the shift increased. Differences in nodal dose are always caused by a combination of factors, 
and there are always exceptions to the rule. For example, from Figure 14b, one of the 
proximal pelvic nodes on the left side of the patient decreased in dose when the applicator 
system is shifted to the left side by 3-mm. However, for the same patient, the system shift 
also moved posterior in the second ICBT fraction, by 1.1-cm, thus causing decrease in 
proximal pelvic nodal dose.  
 46 
Another factor which would result in differences in pelvic node doses between the 
first and second ICBT fraction is ovoid size. In theory, changes in ovoid size would result in 
dose distribution variations, which potentially can lead to dose changes to the proximal 
pelvic nodes. However, in the patient cohort used in this study, only one of the ovoids used in 
a single ICBT fraction was medium sized. Since all remaining ovoids were small, no 
conclusion can be made about nodal dose differences caused by ovoid size changes. 
2.5.2 Nodal Dose Variations in the Distal Pelvic Region 
Compared to the proximal pelvic nodes, the distal pelvic nodes had a more negative 
mean difference in mean nodal dose (-46.8 cGy) and a smaller 1SD (55.3 cGy). This shows 
that the dose contribution to the distal pelvic nodes was almost always lower during the 
second ICBT fraction. This could potentially be caused by tumor shrinkage between the first 
and second ICBT fractions, necessitating a more conformal dose distribution. Correlation 
tests showed that the difference in distal pelvic nodal dose was significantly correlated 
(p<0.01) with tandem angle and the total magnitude of the applicator system shift. Plotting 
tandem angle versus dose change (Figure 14c), we see that with the exception of one patient, 
dose decreased when tandem angle changed during the second ICBT fraction. This is 
expected because dose to the distal pelvic nodes is mainly contributed by the tip of the 
tandem. Rotating the tandem away from the midline where the nodes are located will move 
the dose away. Figure 14d shows that as the system was shifted further away from its original 
location, dose to the distal pelvic nodes decreased. This is reasonable since most shifts in 
system between the first and second ICBT fractions were in the anterior and inferior 
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direction, as shown in Figure 11. Both shift directions will move the dose cloud away from 
the distal pelvic nodes. 
For the seven patients with positive distal pelvic nodes, tandem length differences 
varied between -1 cm to 1 cm between ICBT1 and ICBT2. We originally hypothesized that 
tandem length difference significantly correlates with distal pelvic nodes because increases in 
tandem length would move the tandem tip closer to the nodal regions and the opposite effect 
occurs when tandem length is shortened. However, correlation tests showed no significance 
between the two factors. The reason for that is the location of the tandem tip relative to 
patient anatomy is dependent on two factors, tandem length and system location in the SI 
direction. For example, one of the patients with decreased distal pelvic nodal dose from the 
second ICBT fraction also had a 1-cm longer tandem in ICBT2. However, its system location 
shifted 1.8 cm in the inferior direction. The tip of the tandem is actually 0.8-cm lower in the 
second ICBT fraction, thus causing lower distal pelvic nodal dose. Therefore, tandem length 
alone is not a predictor of nodal dose differences. 
2.5.3 Differences in Result between Mean Dose and D90 
Because nodes are volumetric structures, it is not trivial to pick a point dose to 
describe the dosimetric properties of the entire nodal volume. Traditionally, mean dose has 
been used to describe nodal dose since nodes are typically small. However, when the dose 
gradient within the nodal structure is high, which is normally the case for ICBT, prescribing 
based on mean dose could lead to areas of underdose. Therefore, in addition to studying 
differences in mean dose, we studied differences in D90. Prescribing nodal boost on the basis 
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of D90 guarantees that underdosage may occur in at most 10% of the target. For proximal and 
distal pelvic nodes, the mean±1SD differences between ICBT1 and ICBT2 were closer to 
zero when D90 is used instead of mean dose: 5.2±69.8 cGy and 8.6±85.1 cGy for proximal, 
respectively, and -21.9±38.4 cGy and -46.8±55.3 cGy for distal, respectively. There results 
show that because of the dose gradient in the nodes, there are fewer differences in nodal dose 
in the low dose region. Using mean dose to represent entire nodal dose when analyzing nodal 
dose differences from independent ICBT fractions will result in an overestimation in the low 
dose region, thus not cause underdosage in the nodes. 
2.5.4 Limitations and Assumptions 
In this work, we made several assumptions. First, we assumed that the film images 
were orthogonal and were obtained exactly at 0° and 90°. However, although very close, this 
may not be exact for every patient because the films were obtained in the operating room 
with a portable computed radiography system. The film plate and x-ray unit may not be 
exactly perpendicular since they are independent entities. However, during treatment 
planning in Oncentra, common points on the orthogonal films were used by the treatment 
planning system to create a three-dimensional space model as accurately as possible. This 
ensures that the dose distribution is correct even when the films are not exactly orthogonal. 
Also, since DRRs are generated at exactly 0° and 90°, aligning them to films that are not 
exactly orthogonal might create misregistration. Second, we assumed that nodal regions are 
not deformed by applicator insertions. Previous studies at our institution have shown that 
applicator insertion has minimal effect on dose distribution of the nodes (90). Finally, the 
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method used to normalize ICBT prescription—normalizing ICRU point A dose—is crude. 
Although point A is one of the methods of evaluating dose prescription, it certainly does not 
provide all the information about the dose distribution. However, normalizing point A dose 
does improve consistency and is better than not normalizing at all. 
2.6 CONCLUSION 
We have demonstrated that the mean dose to the pelvic nodes can differ by up to 1.9 
Gy between independent ICBT fractions. Tandem angle and total system shifts were found to 
impact distal pelvic nodes while AP/PA and lateral shifts were found to impact proximal 
pelvic nodal dose. Intracavitary brachytherapy can make a significant contribution to the total 
dose delivered to pelvic lymph nodes. Although the dose delivered from a single system is 
often a good predictor of the overall contribution from brachytherapy, in some cases the dose 
delivered from separate treatments in the same patient can vary significantly. This should be 
carefully considered in the overall planning of treatment for patients who have evidence of 
lymph node metastasis.  
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Chapter 3: Voxel-by-Voxel Bladder and Rectum Dose Accumulation 
between External Beam Radiation Therapy and Intracavitary 
Brachytherapy 
3.1 SPECIFIC AIM 2 
Develop and validate deformable image registration methods for the use of 
volumetric summation of bladder and rectum dose from ICBT to an external beam planning 
CT image set. 
3.2 INTRODUCTION 
3.2.1 Importance of Accurately Evaluating Total Bladder and Rectum Dose for the 
Prescription of Nodal Boost 
During the prescription of external beam nodal boost, dose to the bladder and rectum 
is a major constraint on how much radiation can be delivered to the positive lymph nodes. 
For radiation therapy of cervical cancer, dose tolerances for maximum bladder and rectum 
point dose are 80 Gy and 75 Gy, respectively (91). As mentioned in Chapter 1, maximum 
doses to the bladder and rectum can be estimated by summing the EBRT prescription dose 
(this is done because a great portion of bladder and rectum are included in the primary EBRT 
field) with ICRU bladder and rectum point from ICBT. However, when conformal methods 
such as IMRT are used, this method becomes invalid because IMRT dose is heterogeneous 
with unpredictable hot and cold spots. Unless the maximum dose points from both EBRT and 
ICBT coincides at the same spot, simple dose summation can only represent the worst case 
 51 
scenario and total organ dose will be overestimated. In order to accurately determine 
maximum organ dose, dose summation of bladder and rectum must be performed 
volumetrically.  
3.2.2 Image registration 
Image registration is the process of transforming different sets of data into one 
coordinate system. The process involves a ‘static’ and a ‘moving’ image, with the moving 
image transformed into the coordinate system of the static image. There are two major types 
of image registration, rigid and deformable. Rigid registration aligns two image sets by 
rotation, translation, scaling, or shearing. Since each of these transformations provides 3-
degrees of freedom (ie. roll, pitch, and yaw for rotation and RL, AP, and SI shifts for 
translation) there are a total of 12 possible degrees of freedoms for rigid registration. Because 
rigid registration is a global process, its applications are limited and mostly used for cases 
where the anatomy does not change between images. In radiation therapy, rigid registration is 
mostly used in image guided radiation therapy (IGRT) where daily x-ray or CT images are 
taken prior to treatment and compared to digital reconstructed radiographs (2D/2D matching) 
or planning CT (3D/3D matching) respectively, for daily patient setup (92-94). 
For organs that change shape non-rigidly, such as bladder and rectum, rigid 
registration is inadequate and deformable image registration (DIR) must be used. DIR is a 
voxel mapping process. Instead of registering the images globally, the algorithm looks to find 
corresponding voxels on the static and moving images. Since each voxel is registered 
independently, the number of degrees of freedom becomes infinite. There are two major 
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categories of DIR algorithms, feature-based and intensity-based. Feature-based algorithms 
are also often referred to as point-based or model-based methods. It extracts features, such as 
points, curves, and surfaces on the static and moving images to finds its correspondence (95-
99). Feature-based methods are normally very fast but require robust feature extraction to 
produce accurate results. On the other hand, intensity-based methods only require 
information from the image intensity values (100-104). It finds correspondence by 
maximizing an intensity similarity measure while also producing smooth transformations. 
Image intensity algorithms involve excessive computational power and pre-registration of the 
static and moving images must be performed to prevent the algorithm from being trapped by 
local minima. 
Although there are differences between feature and intensity-based methods, both 
result in a vector field describing the transformation between the static and moving image. 
The field contains vectors indicating the direction and magnitude of transformation needed 
for each voxel on the moving image to match its corresponding voxel on the static image 
(Figure 15). The deformation field by itself is not very useful in radiation therapy. However, 
it can be used as a guide for contour and dose deformation, depending on the clinical needs. 
The deformation field is applied to the contours or dose from the moving image so users can 
view and evaluate them on the static image. 
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Figure 15: Example of a static (inhale) and a moving (exhale) image taken from a 4-
dimensional CT image set. Deformation field resulted from DIR are shown on 
the moving image. We can see that in order for the exhale phase to be deformed 
to match the inhale phase, voxels (especially ones near the diaphragm) must be 
transformed inferiorly resulting in expansion of the lungs. 
3.2.3 In-house accelerated demons algorithm 
The intensity-based DIR method used in this project was first proposed by Thirion 
(103). It is referred to as the demons algorithm based on its analogy with Maxwell’s demons 
(105). The demons algorithm uses the intensity of both static and moving images and the 
gradient of the static image to find correspondence between the two. The equation for the 
demons algorithm is: 
?⃗? = (𝑚−𝑠)∇�⃗ 𝑠
�∇�⃗ 𝑠�
2
+(𝑚−𝑠)2                    (1) 
with m and s indicating voxel values on the moving and static image, (m – s) indicating the 
registration force between the images, and ∇�⃗ 𝑠 representing the gradient of the static image. 
Equation 1 is calculated iteratively for each voxel until the solution converges. In areas of 
low gradient, the original demons algorithm becomes inefficient. To solve this problem and 
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increase speed, Wang et al. (104) added an active force to the original diffusion process. If 
we make the assumption that diffusion of the images is bi-directional, the active force is the 
force which allows the static image to diffuse into the moving image. This lowers the number 
of iterations needed for the demons algorithm to converge and increases speed of registration. 
The equation for “accelerated” demons algorithm is: 
?⃗? = (𝑚− 𝑠) × � ∇�⃗ 𝑠
�∇�⃗ 𝑠�
2
+𝛼2(𝑠−𝑚)2 + ∇�⃗ m�∇�⃗ m�2+𝛼2(𝑠−𝑚)2�                    (2) 
The first term inside the second bracket is the passive force as shown in Equation 1 and the 
second term is the active force. The α2 term was added to the denominator of the terms in the 
brackets to limit the step size of each iteration to 1/(2α). Therefore, even with large 
differences between (m – s), the algorithm cannot make large jumps during any iteration. A 
Gaussian filter with a variance of σ2
To further speed up the algorithm, prevents results from being trapped by local 
minima, and limits the effect of large deformations Wang et al. also implemented a multi-
resolution approach (104). The algorithm is initially calculated at an image resolution that is 
much coarse than the original. When the solution converges, the resolution is increased and 
the displacement fields from the previous calculations are used as starting points for the next 
round of iterations.  This process is repeated multiple times until the original image 
resolution is used. 
 is applied to the result after each iteration to smooth, 
suppress noise, and preserve geometric continuity of the deformation field.  
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3.2.4 Using DIR for Dose Summation of Bladder and Rectum 
With increasing number of commercially available image registration software, usage 
of DIR for the purpose of dose summation has increased dramatically in recent years. 
Currently, most dose summation using DIR are performed in regions where anatomical 
deformations are reproducible and small, such as different phases of the breathing cycle in 
the lungs (106). On the other hand, dose summation for bladder and rectum has remained a 
challenging task. Problems caused by extremely homogeneous features and greatly varying 
sizes make accurate voxel-by-voxel registration in the bladder very difficult. In the rectum, 
the major problem with using DIR is the variable rectal filling and gas content. Gas content is 
especially difficult to address because it may not have corresponding voxels on the aligned 
images. Errors arise in our image intensity based DIR algorithm when corresponding voxels 
simply does not exist.  
Volumetrically summing bladder and rectum dose between EBRT and ICBT is an 
even more difficult task. In addition to the problems just described, there are several 
additional issues which need to be considered. First, the ICBT CT images contain the 
brachytherapy applicator, Foley balloon and catheter, and vaginal packing; all are 
nonexistent on the EBRT CT images. Second, the bladder is empty during ICBT which is not 
the case in EBRT, thus causing large bladder deformations between EBRT and ICBT images. 
Finally, the vaginal packing is intended to push the bladder and rectum away from the 
applicator. This causes large and unnatural shifts in bladder and rectum location between 
EBRT and ICBT. The purpose of this project is to develop and validate a voxel-by-voxel 
dose summation method for the bladder and rectum between EBRT and ICBT CT image sets. 
 56 
With more accurate understanding of the total organ dose, radiation oncologists can consider 
nodal boost prescription escalation without any concern about normal tissue complexities.  
3.3 METHODS AND MATERIALS 
3.3.1 Patient Cohort 
Twenty patients were selected retrospectively for this study. All patients were initially 
part of a prospective Internal Review Board approved protocol. The patients had clinical 
stage IB to IVA cervical cancer and were treated between August 2008 and June 2011. 
Patients were selected based on the criteria of having CT image sets for both external beam 
radiation therapy and ICBT. Patients were treated using different types of brachytherapy 
applicators: 14 patients were treated using a unique shielded but CT artifact-free Fletcher-
Suit-Delclos tandem and ovoid applicator (107, 108), 2 received tandem and mini applicator, 
2 received tandem and ring applicator, and 2 received tandem and cylinder applicator. All 
applicators were manufactured by Nucletron (Nucletron, Netherlands), CT compatible, and 
CT image artifact free. It is extremely important that the applicators used do not cause 
artifacts on the CT images because it would compromise image registration results. 
3.3.2 Contour Based Validation Metrics 
One method of validating DIR algorithms is by evaluating deformed contour results. 
Unlike deformed dose, the accuracy of deformed contours can be easily determined. Since 
the human brain can process gray-scale images much more effectively than computers (109), 
bladder and rectum contours delineated by radiation oncologists can be used as the ground 
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truth for DIR validation. In this study, a single radiation oncologist delineated bladder and 
rectum contours on both external beam planning CT images (EBRT-CT) and ICBT planning 
CT images (ICBT-CT). Patient bladders were delineated to include the Foley balloon, and 
patient rectums were delineated from the level of the distal end of the sigmoid colon to that 
of the ischial tuberosities (110). An example of the contours and the DIR results are shown in 
Figure 16. To validate the accelerated demons algorithm for bladder and rectum, we 
deformed radiation oncologist delineated contours from EBRT-CT to ICBT-CT. The 
deformed contours on ICBT-CT were then compared with delineated contours using volume 
ratios, Dice’s coefficient (111, 112), and mean absolute distance. Volume ratio is calculated 
by dividing the deformed region volume by the delineated region volume, Vdeformed/Vdelineated. 
Dice’s coefficients are calculated using the equation:  
𝑠 =  2|𝑋∩𝑌||𝑋|+|𝑌|                    (3) 
where X and Y are the different contoured regions. Dice’s coefficient measures the similarity 
between two contoured volumes. More specifically, the formula represents the size of the 
union of the two sets divided by their average size. The result ranges between 0 and 1, with 0 
being no overlap and 1 indicating perfect agreement. Finally, mean absolute distance is 
calculated by taking the mean of the distances from deformed contours to the nearest point 
on the delineated contour. The evaluation metrics were calculated independently for bladder 
and rectum. 
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Figure 16: Example showing the differences between EBRT-CT and ICBT-CT with the 
bladder (yellow) and rectum (blue) delineated by a radiation oncologist. The 
image on the right shows deformed contours (colorwash) mapped onto the 
ICBT-CT image. One can see that neither bladder nor rectum agreed well with 
radiation oncologist delineated contours. 
3.3.3 Binary deformation 
Evaluating the results using validation metrics presented in Section 3.3.2 have shown 
that bladder and rectum deformation results between EBRT-CT and ICBT-CT were 
extremely poor when image registration relied on image intensities alone (further details will 
be provided in Section 3.4.1). In order to improve registration results, it was necessary to 
provide extra information to the DIR algorithm in addition to the image intensities. Our 
proposed method to improve DIR results was to force the organ boundaries to match. To do 
so, we converted both CT images to binary images based on the delineated contours. All the 
voxel CT numbers within the contours were changed to 1000 and everything outside was 
changed to 0, as shown in Figure 17. Because the demons algorithm forces the moving image 
to diffuse toward the gradient, a definitive binary boundary will force the boundaries to 
match. Once all images were converted to binary and the binary EBRT-CTs were deformed 
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to binary ICBT-CTs, deformation results were evaluated once again using volume ratio, 
Dice’s coefficient, and mean absolute distance. 
 
Figure 17: Example of binary EBRT-CT and binary ICBT-CT generated based on radiation 
oncologist drawn contours. The image on the right shows binary deformed 
contours (colorwash) mapped onto the ICBT-CT image. One can see that 
compared to using image intensities alone (Figure 16), both deformed bladder 
(yellow) and rectum (blue) contours agreed very well with their delineated 
counterparts. 
3.3.4 Voxel-by-voxel Validation Method 
Validating DIR results using contours only provide partial information about the 
overall accuracy of the registration method. Bad boundary agreement means the registration 
results were poor. On the other hand, good boundary agreement means the results are better, 
but is not enough to evaluate the accuracy of registrations for voxels within the contours. In 
order to validate the accuracy of DIR algorithms for the use of dose accumulation, a voxel-
by-voxel method must be used. In this study, we proposed a novel method to generate a pair 
of artificial CT images with known deformation between them so that we are able to test our 
DIR algorithm by comparing the calculated deformation field with the known deformation 
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field. A few criteria must be met for the results to be clinically relevant. First, the artificial 
images must be created using population data in order to represent an entire population, not 
just a single patient. Second, the images must simulate real clinical situations, in our case, 
deformation in bladder and rectum between EBRT-CT and ICBT-CT images. Finally, we 
must know the exact deformation field between the two images in order to use it as ground 
truth.  
The method we used to create population based artificial CT images is based on the 
active shape model proposed  by Cootes et al. (113). The active shape model captures the 
most prominent variations of certain structure from a population of the structure shapes 
through principal component analysis technique. In our method, variations between two 
shapes are represented by a deformation field in a 3D space. The first step is to determine the 
average variability of shapes within a population and calculate the mean deformation, 𝒅. 
Second, the modes of variations, P, are calculated by applying principle component analysis 
to the population of deformation fields. 𝑷 = (𝒑1,𝒑2, … ,𝒑𝑡) is the matrix of the first 𝑡 
eigenvectors in the principal component analysis, which represents the most prominent 
variations (at least 90% of the total variations) deviating from the mean deformation. A new 
deformation can then be generated from the population model using the equation: 
𝑑 = 𝑑 + ∑ 𝑏𝑖𝑝𝑖𝑡𝑖=1                     (4) 
where bi is generated randomly and represents the deformation contributed by the ith mode of 
variation. In order to ensure the deformation is reasonable, a maximum value, 𝐷max, is 
enforced on the generation of random number bi according to equation 5: 
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Using this method, we can generate a new random deformation field, which can be applied to 
a reference CT image set to generate artificial CT images resembling real human CT images. 
We applied the aforementioned method to our patient population to obtain the inter-
patient and intra-patient variations to generate artificial CT images which represent an entire 
population and have clinically relevant deformations between EBRT-CT and ICBT-CT. 
Knowing the inter-patient variations allows the creation of population artificial CT images. 
Intra-patient variations indicate the amount of deformation between EBRT-CT and ICBT-CT 
for each patient. 
To determine inter-patient variations, we first chose one of the 20 patients as the 
reference patient. The reference patient was chosen to represent the approximate median of 
the population. We also made sure the reference CT image sets, termed EBRT-CT Ref and 
ICBT-CT Ref, had high contrast-to-noise ratio and were free of artifacts. To generate the 
inter-patient deformation field for EBRT-CT, the CT image sets of the remaining patients 
were aligned to the reference patient using our DIR algorithm, creating 19 deformation fields 
(EBRTx - EBRT Ref), as shown in Figure 18. The fields were then used to generate the 
population sampled deformation field (Inter-Patient Deformation Field), shown in Figure 19. 
When the Inter-Patient Deformation Field is applied to the EBRT-CT Ref image, it creates an 
artificial CT image (EBRT Artificial CT) which represents the population in the study 
(Figure 20). 
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Figure 18: Using a reference patient to create a group of deformation fields. 
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Figure 19: The group of deformation field is then used to create a inter-patient deformation 
field. 
 
 
Figure 20: Using the Inter-Patient Deformation Field, we generated an artificial population 
CT image. 
To create the population set which represents variability between EBRT-CT and 
ICBT-CT, we first deformed the EBRT-CT to its corresponding ICBT-CT for all patients 
(Figure 21). Once we have the deformation fields for all patients, we generated a intra-patient 
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deformation field using the same method as before (Figure 22). The resulting deformation 
field (Intra-Patient Deformation Field) represents the principle anatomical variations between 
external beam CT images and brachytherapy images. Also, to create the ICBT Artificial CT 
image, we needed to know the deformation field between the two reference images (Ref Def 
Field), as shown in Figure 23. Generating the ICBT Artificial CT image is not as straight 
forward as generating the EBRT Artificial CT image. The detailed process is shown in 
Figure 24. The concept is to first spatially transform the ICBT-CT Ref image to the EB-CT 
Ref image, while retaining ICBT characteristics (contains applicator, Foley balloon, etc.). 
This image with the ICBT characteristics was then spatially transformed into the space of 
EBRT Artificial CT image using Inter-Patient Deformation Field. Finally, we created the 
ICBT Artificial CT image by further applying the Intra-Patient Deformation Field. An 
example of EBRT Artificial CT and ICBT Artificial CT generated using Dmax = 2 is shown in 
Figure 25. The variability between EBRT Artificial CT and ICBT Artificial CT is the Intra-
Patient Deformation Field and that is our known field. 
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Figure 21: Creating a group of deformation fields between external beam CT images and 
brachytherapy images. 
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Figure 22: Using the group of intra-patient deformation fields to create a population 
deformation field between external beam radiation therapy and brachytherapy 
CT images (Intra-Patient Deformation Field). 
 
 
Figure 23: The deformation field between the Reference images (Ref Def Field) is needed for 
creating the simulation ICBT image. 
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Figure 24: In order to create the ICBT Artificial CT, the original ICBT-CT Ref must go 
through a few transformations into different CT image space. 
 
Figure 25: Example of EBRT Artificial CT and ICBT Artificial CT generated using Dmax = 2. 
Since our choice for Dmax is not large, the deformation between the two images 
is not as severe. 
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3.3.5 Validation of Deformation Results 
Using the artificial CT image pairs generated by the method described in Section 
3.3.4, we could validate the deformation results for the bladder and rectum. By subtracting 
the deformed field from the known field, we can quantify differences in the RL, AP, SI 
directions and total magnitude for each voxel. The total magnitude was calculated by taking 
the root of the sum of squares in the three directions. The mean difference of all voxels was 
reported as the error in registration. We then converted the simulated CT images into binary 
images as described in Section 3.3.3 and repeated voxel-by-voxel validation for the bladder 
and rectum. To test DIR accuracy with varying amounts of deformation, we validated the 
normal and binary deformation results with Dmax set at 2, 3.5, and 4.5. 
3.4 RESULTS 
3.4.1 Contour Based Validation 
Results from contour based validations are shown in Table 2 and 3. By using a binary 
method instead of image intensities alone, the deformed contours have shown much better 
agreement with delineated contours. On average, the Dice’s coefficient increased by 0.39 and 
0.41 for the bladder and rectum, respectively. The mean absolute distance decreased by 5.6 
mm for both organs. Typically, when judging similarity of two regions based on Dice’s 
coefficient, which ranges from 0 to 1, a value of 0.7 is considered acceptable and 0.8 is 
considered good. When deforming using normal methods, Dice’s coefficient for the bladder 
and rectum exceeded 0.7 in 8 of 20 (40%) and 0 of 20 (0%) patients, respectively. When the 
criteria is raised to 0.8, only 3 of 20 (15%) bladders and 0 of 20 (0%) rectums exceeded it. 
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On the other hand, when binary methods are used, all 20 bladder and 19 of 20 (95%) rectum 
deformations exceeded a Dice’s coefficient of 0.8. 
Table 2: Evaluation of contour agreement between deformed and delineated for bladder using 
image intensity alone (Normal) and Binary methods. 
 Bladder 
 Normal Binary 
 Mean+1SD Range Mean+1SD Range 
Volume Ratio 1.04+0.45 0.36-1.86 0.98+0.02 0.93-1.01 
Dice 0.57+0.2 0.2-0.88 0.96+0.02 0.92-0.98 
Mean Absolute Distance (cm) 0.65+0.29 0.23-1.06 0.09+0.02 0.05-0.13 
Table 3: Evaluation of contour agreement between deformed and delineated for rectum using 
image intensity alone (Normal) and Binary methods. 
 Rectum 
 Normal Binary 
 Mean+1SD Range Mean+1SD Range 
Volume Ratio 0.91+0.44 0.25-1.88 0.95+0.06 0.75-1.05 
Dice 0.5+0.1 0.3-0.66 0.91+0.04 0.79-0.95 
Mean Absolute Distance (cm) 0.69+0.23 0.39-1.31 0.13+0.07 0.07-0.35 
 
3.4.2 Mean Error from Voxel-by-Voxel Validation 
Mean differences of all voxels between deformed and known deformation fields in 
the RL, AP, SI, and total magnitude are shown in Table 4. The mean error in registration for 
the bladder using image intensity alone (Normal) DIR methods were 0.98 mm, 1.09 mm, -
0.17 mm, and 3.47 mm in the RL, AP, SI, and total magnitude, respectively. Using the binary 
DIR method, the mean errors in registration for the bladder were 0.24 mm, -2.76 mm, -1.33 
mm, and 4.61 mm in the RL, AP, SI, and total magnitude, respectively. For the rectum, the 
mean errors in registration using Normal DIR methods were 0.02 mm, -0.86 mm, -0.37 mm, 
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and 2.74 mm in the RL, AP, SI, and total magnitude, respectively, while the mean errors in 
registration using binary DIR methods were 1.39 mm, 1.54 mm, 3.19 mm, and 5.6 mm in the 
RL, AP, SI, and total magnitude, respectively. Figure 26 shows an example of the histograms 
for bladder and rectum voxel misregistration using normal and binary methods when Dmax is 
set to 2.  
Table 4: Mean errors in registration (mm) for all voxels in the bladder and rectum. 
  Bladder Rectum 
 Dmax 2 3.5 4.5 2 3.5 4.5 
RL Normal 1.38 1.44 0.12 0.09 -0.14 0.11 
Binary 0.84 -0.30 0.19 1.76 1.34 1.09 
AP Normal 1.12 0.86 1.30 -0.51 -1.06 -1.00 
Binary -2.73 -3.25 -2.30 1.95 1.23 1.46 
SI Normal 0.64 -0.70 -0.44 -0.22 -0.12 -0.76 
Binary -1.38 -1.26 -1.35 2.81 3.48 3.28 
Mag Normal 3.32 3.69 3.41 2.51 2.73 2.98 
Binary 4.11 5.09 4.64 5.28 6.08 5.43 
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Figure 26: Histogram of errors in registration between deformed and known deformation 
fields. Both bladder and rectum were analyzed using normal and binary 
deformation methods. Dmax in this example was 2. 
3.5 DISCUSSION 
3.5.1 The importance of voxel-by-voxel validation 
With the increasing availability of commercial software which offers FDA approved 
DIR tools for volumetric dose summation, it is even more crucial to develop voxel-by-voxel 
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validation tools to understand the magnitude of uncertainties associated with DIR algorithms. 
In a recent point/counterpoint published in Medical Physics, the appropriateness of adaptive 
radiation therapy using dose deformation was hotly debated (114). Although both sides were 
debated, the consensus was that accurate DIR is a difficult clinical problem which requires 
full understanding of the limitations from both physicists and radiation oncologists in order 
to be safely used in the clinic. Quantifying registration errors is the first step toward 
understanding limitations and determining appropriate uses of DIR. 
Currently, the three most commonly used methods of voxel-by-voxel DIR validation 
use anatomical landmarks, anthropomorphic phantoms, and mathematical phantoms. In 
regions where anatomical landmarks are easily seen and can be reproduced accurately, 
landmarks are identified on both static and moving images. After DIR between the two 
images, landmarks on the deformed moving image is compared to landmarks on the static 
image. Differences in landmark locations between the two are the errors in registration. Most 
common uses of landmarks for DIR validation are in the thoracic or liver regions where 
bronchial or vessel bifurcations can be accurately identified (96, 115). Another method for 
DIR validation is by using anthropomorphic phantoms which can be physically deformed to 
a known amount. For example, Kirby et al. (116, 117) built a head & neck and a pelvic 
phantom which contains glow in the dark optic markers that are CT transparent. This is 
useful because the optical markers do not influence DIR results. When the phantoms are 
deformed, the deformation fields can be measured optically and compared with DIR 
calculated deformation fields based on the pre and post deformed CT images. Finally, one 
can take a CT image and artificially create simple deformations using software to generate a 
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new CT image. DIR algorithms are tested by deforming the new CT image with the original 
CT image and compared with the applied deformation (104, 118). 
Established methods such as landmarks or phantoms are not ideal for this study. 
Unlike thoracic or liver regions where bronchial or vessel bifurcations can be accurately 
identified, bladder and rectum lack landmark points which may be used for validation. Also, 
building an accurate anthropomorphic volumetric phantom of the female pelvis with the 
ability to mimic bladder and rectum changes after an ICBT applicator insertion is not trivial. 
There are a few reasons why our validation method is novel and advantageous compared to 
other available methods. First, our method utilizes and creates realistic patient CT images 
without having to physically build a phantom. This makes the process extremely simple and 
can be used widely by many clinics with their own patient database. Second, the known 
deformation field is generated using population data. Therefore, the artificial deformations 
are clinically relevant and represent real patient anatomical variations. Third, we have 
provided a method to generate artificial ICBT images while still maintaining the known 
deformation field between it and the artificial EBRT-CT image. Finally, although we only 
validated our method for the bladder and rectum between the EBRT-CT and ICBT-CT 
images, our proposed method can be used for any site and any DIR algorithm. Institutions 
wishing to validate their in-house or commercial DIR programs can easily do so by 
generating artificial images with known deformation fields for their organs of interest and 
patient population using the guidelines provided in this study. 
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3.5.2 Comparing Binary and Normal Methods Using DIR Evaluation Metrics 
As Table 2 and 3 have shown, using image intensity alone for DIR of EBRT-CT to 
ICBT-CT resulted in very poor agreement at the boundaries. This is not a surprise since we 
already anticipate deformations in the bladder and rectum region is large. Also, constraints 
are placed in the DIR algorithm to prevent large “unrealistic” deformations. When 
deformations are actually large, the maximum deformation vector magnitude allowed is the 
calculation result instead of the true deformation. Using image intensities alone, the mean 
Dice’s coefficient for both bladder and rectum is only around 0.5 or 50% similarity between 
deformed and delineated contours. Even without voxel-by-voxel validation, we can make the 
conclusion that image intensity alone will not be appropriate for dose summation between 
EBRT-CT and ICBT-CT. If the boundaries are incorrectly deformed, voxel registrations 
within the boundaries are going to be incorrect as well. By converting the images to binary 
images, we forced the boundaries to match, which in theory should improve registration 
results. Our results have shown that by using the binary method, the boundaries matched 
extremely well even with large deformations. 
Before discussing the results from our voxel based validation method, the limitations 
and drawbacks of the binary method need to be listed. First, human interaction is required for 
the binary process. The organs of interest must be manually delineated on both static and 
moving images. This is not required if using image intensity alone. The accuracy of the 
deformation results also becomes highly dependent on the accuracy and consistency of the 
delineated contours. Second, by converting images to binary, we lose the image information 
within the contours. Since all voxels within the volume are have CT number of 1000, the 
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deformations of the inner voxels are essentially interpolated based on where they are located 
and the amount of deformation at the boundary. 
Comparing registration results for the bladder and rectum on our artificial images. We 
observed that overall errors in registration are less for the normal image intensity 
registrations. This is unexpected since the boundary validations have shown better results 
using the binary method. Upon reviewing the artificial images, we concluded that one of the 
main reasons image registration results were good for our artificial images was because the 
chosen Dmax were small. Since Dmax determines the maximum amount of deformation that 
could be created, we did not generate the extreme organ deformations which were observed 
between EBRT-CT and ICBT-CT. To test this theory, we increased the Dmax value from 2 to 
3.5 and 4.5. When we increased Dmax, DIR becomes less accurate for both image intensity 
and binary registration methods, as shown in Table 4. We also observed that increasing Dmax 
affected image intensity registrations more than binary registration. This is because binary 
registrations are much better at handling large deformations than image intensity based 
registrations. Figure 27 shows a sagittal view of the bladder and rectum with the total 
magnitude of error for each voxel. For image intensity based registration (Normal), the 
regions with accurate and inaccurate registrations were scattered throughout the region. For 
binary registration, the more accurate regions were in areas where deformations were small. 
On the contrary, less accurate regions were located in areas with large deformations. 
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Figure 27: Sagittal view of total magnitude registration errors for normal and binary methods 
for each voxel. One can see that errors in registration on the normal method 
occurred at places where voxels lacked correspondence between the EBRT-CT 
and ICBT-CT images. For the binary method, registration errors were greatest 
in regions where deformation was large. 
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Comparing our registration results to results found by other research groups, we 
found that our results were very much in line with published data, which varied between 2 to 
7 mm (96, 104, 115-118). We found that mean errors in bladder and rectum registrations are 
3.5 mm and 2.7 mm for image intensity registrations, respectively, and 4.6 mm and 5.6 mm 
for binary registrations, respectively. The advantage of our voxel validation method is that 
our results are patient population, organ, and DIR algorithm dependent. The results of this 
work are specific to our demons algorithm and for bladder and rectum deformations between 
EBRT-CT and ICBT-CT. 
3.6 CONCLUSION 
We have created a method to improve DIR of the bladder and rectum between an 
external beam CT image and an ICBT CT image. We also developed a voxel-by-voxel 
validation method to quantify the errors in registration. By doing so, we have explored the 
limitations in such DIR process so that physicist and radiation oncologists can have better 
understanding of what the deformation results mean and how it can be used clinically. 
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Chapter 4: Beam Angle Specific Margins to Account for Anatomical 
Uncertainties during Proton Therapy in Nodal Boost Planning for Cervical 
Cancer 
4.1 SPECIFIC AIM 3 
Calculate nodal boost planning margins needed for proton therapy to account for 
interfractional anatomical variations. 
4.2 INTRODUCTION 
In recent years, proton therapy has become more mainstream and accessible to 
patients needing radiation therapy. According to the Particle Therapy Co-Operative Group, 
as of February 2013, there are 11 centers in operation and 8 under construction in the United 
States alone (119). The main attraction of protons therapy is that the beam has finite range 
and delivers almost all of its energy at the end of its range (termed the Bragg peak); almost 
no energy is deposited beyond the Bragg peak. Clinically, this feature of protons is extremely 
advantageous because all organs beyond the distal edge of the beam can be spared from 
radiation. Unfortunately, CT number, beam energy, setup, and patient motion uncertainties 
can all affect the proton range (120, 121). Currently, a simple method is used to account for 
such uncertainties: 3.5% of the spread-out Bragg peak is applied as distal and proximal 
margins, as proposed by Moyers et al. (122). However, current methods rarely explicitly 
account for patient’s interfractional anatomy changes, which could have a big effect on target 
coverage. 
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In patients with involved pelvic lymph nodes, nodal boost with radiation (“boost”) is 
given to increase the total dose to the involved nodes to 60 to 66-Gy (79). Although nodal 
involvement from cervical cancer may occur anywhere along the lymphatic drainage 
pathway, cervical cancer most commonly spreads to the external iliac nodes and common 
iliac nodes (77, 78). Currently, though nodal boost doses are typically delivered using 
external beam photon therapy, proton therapy can generate theoretical dose distributions 
unmatched by photons for nodal boosts. For example, a single PA proton beam can be used 
to deliver conformal dose to external iliac nodes. Small bowel will be spared because it lies 
beyond the distal margin. However, uncertainty related to interfractional anatomical changes 
need to be considered thoroughly in order to use proton therapy to target the nodal boost 
volume.  
Dosimetric differences caused by interfractional anatomical variations are magnified 
in nodal boosts because a very small target is irradiated over a small number of fractions. 
Any variation in anatomy in the beam path can cause the proton beam edge to shift off the 
target, resulting in undercoverage in either the distal or proximal end of the target. Shifts in 
distal and proximal edges of the beam may also potentially move the high dose region into 
adjacent normal tissues, causing complexities. Thus, adequate distal and proximal margins 
must be used during proton nodal boost planning to account for anatomical uncertainties, in 
addition to the uncertainty of CT numbers (122). Modeling and predicting interfractional 
anatomical changes is not trivial. Anatomical variations are dependent on target location, 
target size, and beam angle. 
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The purpose of this aim was to develop a general approach to determining the 
margins needed to account for interfractional anatomical variations during proton therapy. 
We applied this approach to determine the optimal beam orientation and required margins for 
delivery of radiation boost to external iliac and common iliac nodes using proton beams. 
4.3 METHODS AND MATERIALS 
4.3.1 Patient Cohort 
Patients in this study were originally part of an Institutional Review Board approved 
prospective study of internal organ motion in cervical cancer patients (22). Images obtained 
from the previous study were retrospectively evaluated in this study. CT images from 16 
patients with Stage IB2 through IIIA cervical cancer who had been treated with concurrent 
chemoradiation without hysterectomy were used for this study. Eight patients had Stage IB2 
disease, 1 had Stage IIA disease, 6 had Stage IIB disease, and 1 had Stage IIIA disease. Each 
patient underwent a simulation CT scan prior to treatment planning, first with the bladder full 
and then with the bladder empty, performed with a Philips AcQSim3 CT scanner (Philips 
Medical Systems, Andover, MA) using our standard pelvic CT imaging protocol. All patients 
received primary EBRT followed by 2 fractions of PDR ICBT. The EBRT fractionation 
schemes used were 43.2 Gy in 24 fractions (6 patients) and 45 Gy in 25 fractions (10 
patients). Patients also underwent a CT scan weekly prior to treatment, performed with an in-
room CT-on-Rails system (GE Healthcare, Milwaukee, WI). Patients were weighed prior to 
chemotherapy and at weekly check-ups to ensure no sudden weight loss or gain. 
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4.3.2 Automatic Contour Delineation 
In each patient, the goal was to design the radiation fields to cover the most 
frequently involved external iliac and common iliac lymph nodes as identified in a study 
recently published by Fontanilla et al. (77). To avoid interobserver and contour delineation 
uncertainties, DIR using an in-house developed software (104) was used. The study by 
Fontanilla et al. included an atlas in which PET-positive nodal locations from 45 patients 
were summarized on a single reference CT scan. We designed the clinical target volume 
(CTV) used in this study to cover external iliac nodal regions that were positive in at least 
14% of patients in the Fontanilla et al. study and common iliac nodal regions that were 
positive in at least 12% of the patients in that study. Since positive nodes may occur 
anywhere along the lymphatic drainage, nodal regions positive in 12% of the patients is 
considered high occurrence. Nodal contours from the atlas were deformed to each planning 
CT. All deformed contours were expanded and smoothed using contouring tools in the 
Pinnacle TPS version 9.0 (Philips Medical Systems, Andover, MA). Then, all contours were 
verified and approved by a radiation oncologist. 
4.3.3 Patient Setup 
Currently, for proton therapy delivered at our institution, in-room kilovoltage x-ray 
images are used for daily treatment setup alignment. The limitation of such a technique is 
that only bony anatomy is visible in the image. In the case of nodal boost treatments, bone-
based alignment method is sufficient since lymph nodes are typically fixed with respect to 
bony anatomy. To simulate treatment scenarios for the current study, we delineated a pelvic 
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bony region of approximately 2-cm in cranial-caudal dimension near the external iliac nodes 
and a second region at the superior portion of the sacrum. Those regions were used as 
alignment surrogates for the external iliac and common iliac nodes, respectively. Nodal 
contours from planning CT were transferred to weekly CT images using rigid image 
alignment of the delineated bony structures (92, 123). The rigidly aligned nodal contours on 
the weekly images represented the actual dose delivery region without daily patient setup 
uncertainties. Illustration of the process can be seen in Figure 28. 
 
Figure 28: Simulation of daily treatment setup by transferring target contours (yellow) from 
Reference to Daily CT image sets using bony structures (red). 
4.3.4 Calculation of anatomical changes 
In this project, we used the ray-tracing method to determine anatomical changes. The 
method calculates the water-equivalent path-length of parallel rays in the direction of defined 
beams from the patient surface to the distal and proximal surfaces of the target. The 
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dimension of each ray size is equivalent to the voxel dimensions of the CT images. 
Measuring differences in water-equivalent path-length between planning and weekly CT 
images indicates the magnitude of change in the proton beam range. To evaluate the impact 
of beam angle on the magnitude of range change due to anatomical variation, we evaluated 8 
gantry angles for the treatment of common iliac nodes (from 0° to 315°, at 45° intervals) and 
3 gantry angles (90°, 180°, and 270°) for the treatment of external iliac nodes. Using the ray-
tracing algorithm, the distal and proximal edges of the nodal contours at each angle for every 
CT image set were calculated. As shown in Figure 29, each ray-trace results in a 2-
dimensional matrix showing the water-equivalent path-length from the beams-eye-view. 
 
Figure 29: A ray-tracing method was used to determine the water-equivalent path-length 
(WEPL) from the patient surface to the distal and proximal edges of all targets. 
Ray tracing is parallel to the treatment beam direction. This method results in 
two 2-dimensional matrices that represent the distal and proximal WEPL map 
for each target on any particular computed tomography scan. 
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4.3.5 Margin calculation 
To determine the margin required to ensure coverage of the target in each weekly CT 
image, the reference water-equivalent path-length matrix (obtained on the planning CT) was 
subtracted from each weekly matrix, pixel by pixel, for both distal and proximal edges 
(Figure 30). The margin required to account for anatomical variations in the beam path on 
any given weekly fraction was defined as the difference corresponding to the 95th percentile 
of the differences of all the pixels. To determine the margin needed to cover the entire 
population, all weekly margins were combined, and the mean plus 2 standard deviation was 
used as the population margin. 
 
Figure 30: After the water-equivalent path-length (WEPL) maps for both distal and proximal 
surfaces were obtained on all planning and weekly computed tomography (CT) 
images, the reference planning maps were subtracted from each daily map to 
obtain the variation maps. The WEPL difference value to cover 95th percentile 
of the pixels was used as the margin needed to account for anatomical variations 
on that particular fraction. Multiple measurements were obtained for each repeat 
CT image and a group of patients. 
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4.3.6 Proton Therapy Planning Test Case 
To determine the advantages and feasibility of using protons for nodal boosts for 
cervical cancer, data from a typical cervical cancer patient who had been treated with photon 
nodal boosts were used. The original clinical prescription for nodal boosts was 10 Gy in 5 
fractions to the external iliac nodes and 6 Gy in 3 fractions to the common iliac nodes. Three-
field IMRT plans were used for each node. The CT images and all contour delineations were 
transferred from the original photon therapy plan to the proton therapy plan. Bowel was 
delineated as the entire peritoneal potential space of bowel. A simulated proton therapy plan 
was performed in the Eclipse Proton TPS (Varian Medical System, Palo Alto, CA). Two 
single-field, uniform-dose scanning proton beams, 90° (right lateral) and 180° (PA), were 
chosen to treat the common iliac region, and a single, 180° (PA) beam was used to treat the 
external iliac nodes. These angles were chosen because they are associated with the least 
interfractional anatomical variation (more details shown in Section 4.3.2). Current clinical 
planning margins, which are 3.5% of the SOBP plus 3 mm, were applied to both distal and 
proximal edges to account for stopping-power-ratio and dose calculation uncertainties, 
respectively. The anatomical variation margins derived from this work were also included in 
addition to current clinical margins.  The target dose was normalized to provide coverage 
similar to that with the original photon therapy plan. Differences in normal tissue dose were 
analyzed. 
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4.4 RESULTS 
4.4.1 Patient Weight Changes 
Out of the 16 patients, 6 patients had 4 weekly CT scans, 9 patients had 5 weekly CT 
scans, and 1 patient had 6 weekly CT scans. The mean relative weight change between 
weekly and planning CT scans in this cohort of patients was -2.3±2.7%, and the maximum 
relative change was -8.6% (the negative sign represents a weight loss). Seven of the 16 
patients had maximum weight loss of greater than 5%. 
4.4.2 Distal and Proximal Margin Requirements for Common and External Iliac Nodes 
Results for both common iliac and external iliac nodes are shown in Figure 31. For 
the common iliac nodes, the angles with the greatest anatomical variations were 0° (AP), 45° 
(left anterior oblique [LAO]), and 315° (right anterior oblique [RAO]). The population 
proton margin requirements to account for interfractional variations for 0°, 45°, and 315° 
were 1.9 cm, 1.7 cm, and 2.4 cm, respectively, for the distal edge and 3.0 cm, 2.6 cm, and 3.5 
cm, respectively, for the proximal edge. The angles with the least anatomical variations were 
90° (left lateral) and 180° (PA). The population planning margin requirements for 90° and 
180° were 0.8 cm and 0.9 cm, respectively, for the distal edge and 1.7 cm and 1.4 cm, 
respectively, for the proximal edge. The remaining angles, 135° (left posterior oblique), 225° 
(right posterior oblique), and 270° (right lateral), fell somewhere between the 2 extremes, 
with population margin requirements of 1.2 cm, 1.3 cm, and 1.3 cm, respectively, for the 
distal edge and 2.1 cm, 2.1 cm, and 1.8 cm, respectively, for the proximal edge. 
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For the external iliac nodes only interfractional anatomical uncertainties in PA and 
lateral angles were analyzed because of the strong preference to avoid the central pelvis. For 
left and right external iliac nodes, the PA margin requirements were 0.8 cm and 0.7 cm, 
respectively, for the distal edge and 1.0 cm and 1.3 cm, respectively, for the proximal edge. 
Lateral margin requirements for the left and right external iliac nodes were the same (0.3 
cm), for the distal edge and 1.2 cm and 1.3 cm, respectively, for the proximal edge. 
Combining the left and right nodes and choosing the worst case between the two in each 
fraction revealed that the population margin requirements for the PA beams were 0.9 cm and 
1.3 cm for the distal and proximal edges, respectively. For lateral beams, the population 
margin requirements were 0.4 cm and 1.4 cm for the distal and proximal edges, respectively.  
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Figure 31: Range margins for common (a) and external iliac (b) nodes were analyzed. 
Several angles were selected to test the impact of beam angle on the magnitude 
of change in the proton beam range due to anatomical variation. Box graphs 
showing median, 75th percentile, 90th percentile, and outliers for both distal 
and proximal variations are shown. 
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4.4.3 Comparison of Photon and Proton Dose Distribution in Test Case 
We found that the major difference between photon and proton nodal boosts was 
bowel sparing. Figure 32 shows the dose distribution and dose-volume histogram differences 
between IMRT and the single-field, uniform-dose proton plan for the sample patient. The 
difference in target coverage between the 2 modalities was essentially zero, by design. 
However, the proton dose to the bowel was approximately half the photon dose to the bowel 
at all dose levels. Using metric guidelines from the Quantitative Analysis of Normal Tissue 
Effects in the Clinic (QUANTEC) effort (23) indicated that the dose to the 195 cc of the 
bowel region increased from 2.8 Gy with protons to 5.7 Gy with photons. 
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Figure 32: Differences between the dose-volume histograms for intensity-modulated 
radiation therapy (IMRT) and proton therapy for both common iliac and 
external iliac nodes. Three-field IMRT plans were used for each node. A 2-field 
proton plan was used for the common iliac nodes, and a single proton posterior-
anterior field was used for the external iliac nodes. The small bowel dose was 
reduced by half with proton therapy. 
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4.5 DISCUSSION 
Accurate targeting in proton therapy requires the knowledge of range uncertainties 
during treatment delivery. Interfractional variation of anatomy outside the treatment target 
could introduce range uncertainties to cause proton beams to shift distally or proximally. 
Adequate margins are necessary to ensure accurate proton beam delivery especially for 
treating small targets. Large anatomical variations could potentially shift the distal or 
proximal edge of the proton beam completely out of the target. It is also important to 
evaluate range uncertainties as a function of proton beam angles. In this study, we proposed a 
general approach to construct margins to account for interfractional anatomy variations. We 
used a ray-tracing method and repeat in-room CT images to quantify beam-specific margin 
requirement for a group of cervical cancer patients. 
Previous studies by Hui et al. and Wang et al. looked at the effects of interfractional 
anatomical variation during proton therapy (124, 125). However, in those studies, the 
anatomical sites examined were lung and prostate, and the focus was on evaluating the 
adequacy of established clinical treatment margins. This work went a step further by 
calculating the actual required margins. Using protons to boost the dose to the nodes for 
cervical cancer is a new idea, and the results from this work provide radiation oncologists 
with adequate information to delivery such therapy with confidence. 
4.5.1 Beam Angle Dependence of Interfractional Anatomical Variations 
Our results indicate that proton beam uncertainties are very dependent on beam angle 
selection. Beams passing through the bowel region required margins 2 to 3 times as large as 
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beams passing at other angles. This is not surprising since bowel contents can vary greatly 
from day to day, as illustrated in Figure 33a and b. In addition, beams passing through the 
bowel are not favorable since bowel doses after primary EBRT and brachytherapy may 
already be close to the maximum tolerated dose. Proton beams at 135° (left posterior oblique) 
and 225° (right posterior oblique) required less margin than beams passing through the 
bowel. However, the margin required to account for uncertainties at those angles was still not 
small. As seen in Figure 33c and d, daily patient setup can greatly affect how much 
subcutaneous adipose tissue lies between the patient’s skin surface and the target. This is the 
main cause of interfractional variations at those angles. The angles with the lowest 
uncertainties were the PA and lateral angles. These angles were less affected by bowel 
content and setup uncertainties. 
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Figure 33: Examples of anatomical variations at different beam angles. Bowel path 
differences can be seen clearly in (a) and (b) for the 315° (right anterior oblique) 
angle. Differences in subcutaneous adipose tissue can be seen in (c) and (d). In 
both cases, differences in range are greater than the spread-out Bragg peak of 
the beam. 
4.5.2 Differences in Distal and Proximal Margin Requirements 
Interestingly, our results showed a difference in the magnitude of the required distal 
and proximal margins. In theory, variations in the beam path should be random. Distal and 
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proximal required margins should be comparable. However, on average, the required distal 
margin was 0.8 cm (range, 0.2 to 1.1 cm) smaller than the required proximal margin. We 
hypothesized that weight loss was a major contributor to the asymmetric margin 
requirements. Two-tailed Spearman’s rho correlations were used to test the statistical 
significance of the correlation between patient weight change and margin requirements. For 
common iliac nodes, margin requirements were significantly correlated (p<0.01) with weight 
change for all angles for both distal and proximal margins except for distal margin 
requirements at 270° (right lateral). For external iliac nodes, margin requirements were 
significantly correlated with weight change for all proton beam angles. Correlation 
coefficients also showed that the magnitude of the proximal margin was directly proportional 
to the magnitude of weight loss and the magnitude of the distal margin was inversely 
proportional to the magnitude of weight loss. This is reasonable since proximal margins are 
required when patients lose weight because the beams will pass through less tissue, thus 
overshooting the target. Overshooting the target will result in inadequate coverage at the 
proximal edge. However, from a dosimetric point of view, the proximal fall-off of a proton 
beam is gradual. The dosimetric impact may not be as significant as in the distal end. 
4.5.3 Differences between Common and External Iliac Nodal Margin Requirements 
Differences between margin requirements for common and external iliac nodes were 
analyzed. For PA beams, margin differences between the 2 nodal regions were less than half 
a millimeter. In the lateral directions, common iliac nodes required an average increase of 0.5 
cm and 0.7 cm in the left and right sides, respectively. Once again, weight loss may be a 
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major contributor to the difference in the lateral beams. Because patient weight loss usually 
has the largest effect in the abdominal region, common iliac nodes are affected more. 
4.5.4 Potential Small Bowel Sparing using Protons for Nodal Boost 
Comparison of the IMRT plan with the single-field, uniformly optimized dose proton 
plan revealed that the sparing in bowel dose was large. The QUANTEC guidelines 
recommended that the volume of bowel treated to 45 Gy be less than 195 cc (23). However, 
that dose limit could possibly already have been reached during primary EBRT. Therefore, it 
is crucial that the small bowel receive minimal additional dose from the boost. With the extra 
anatomical margins added into our proton therapy plan, it was impossible to totally avoid the 
bowel region. Nevertheless, the dose to the bowel was reduced by half if protons were used. 
With that stated, the main focus of this project was angle and margin determination. A 
dosimetric comparison between proton and photons is beyond the scope of this study. 
4.5.5 Assumptions and Limitations 
One limitation of this study is the use of a simple ray-trace method. Although this 
method is fast, it does not account for scatter within the medium. However, the ray-tracing 
method as a fast dose approximation has been validated by Park et al. (126). In their work, 
gamma analysis under 3% dose and 3-mm distance-to-agreement criteria was greater than 
90%. Another limitation of our study is that CT images were obtained weekly instead of 
daily. In our clinic, nodal boosts are given in a single week in 5 fractions. Patient may not 
lose much weight during one week. In this study, we used weekly CT images (because of 
their availability) and the interfractional anatomical variations are likely to be larger than the 
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actual interfractional variations in one week. Therefore, the results from this work might 
have overestimated the margin requirements, especially for patients who lose significant 
weight. 
4.6 CONCLUSION 
We have demonstrated a systematic approach to determine population-based 
anatomical margin requirements for proton therapy. Our ray-tracing approach is not limited 
to the pelvis and nodal structures; it is universal and can be applied to any disease site. The 
results of our study indicate that in cervical cancer patients requiring nodal boosts, the 
optimal treatment angles for common iliac nodes are 90° (left lateral) and 180° (PA) with 
additional 0.8-cm and 0.9-cm margins, respectively. For external iliac nodes, lateral and PA 
beams required additional 0.4-cm and 0.9-cm margins, respectively. These results will allow 
for safe delivery of proton therapy when delivering nodal boosts to patients with cervical 
cancer. 
  
 97 
Chapter 5: Conclusion 
5.1 SUMMARY OF THE PROBLEMS, PURPOSE, AND HYPOTHESIS 
During a multi-course, multi-modality treatment of cervical cancer, the primary 
EBRT, ICBT, and external beam nodal boost all contribute substantial dose to the lymph 
nodes. In many cases, primary EBRT delivers sufficient dose to the nodes to treat 
microscopic diseases. Radiation boost is only given to patients with positive lymph nodes 
requiring dose escalation. Prescription of radiation for nodal boost is not straightforward. 
Many considerations must be taken into account to prevent underdosing the nodal target, 
which may lead to recurrence or metastasis of disease, while also not overdosing, which 
could cause normal tissue complexities. Accurate radiation prescription for nodal boost 
require exact knowledge of previously delivered dose from primary EBRT and ICBT to both 
the targeted nodes and normal tissues. At MD Anderson, because the second PDR ICBT 
fraction is delivered post nodal boost, some assumptions about the 2nd ICBT fraction must 
be made during prescription of nodal boost, which require prior knowledge of potential 
differences between the two ICBT fractions. Also, current methods of summing bladder and 
rectum dose using maximum dose points could overestimate when conformal methods such 
as IMRT are used. Volumetric dose summation needs to be used for more accurate 
understanding of dose distributions in the normal organs. Prescription of nodal dose is only 
half of the difficulty; the other half is dose delivery. When photons are used, setups of beam 
angles always involve tradeoffs and compromises to avoid normal tissues. 
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The purpose of this project is to improve external beam radiation therapy of 
lymphatic nodal boost during a course of cervical cancer treatment by: 1) Quantifying 
interfractional uncertainties. 2) Developing and validating dose accumulation tools between 
external beam radiation therapy and brachytherapy. 3) Exploring alternative treatment 
modalities. 
The hypothesis of this project is separated into three parts. First, rigid 2D-3D image 
alignment between films and CT images can be used to quantify nodal dose differences from 
independent ICBT insertions. Second, deformable image registration can be used to sum 
normal tissue dose from EBRT and ICBT. Third, ray-tracing methods can be used to 
determine interfractional anatomical variation margin requirements for proton therapy of 
nodal boost. 
5.2 SPECIFIC AIMS 
5.2.1 Specific Aim 1 
Specific Aim 1 was to quantify variations in pelvic nodal dose due to applicator 
placement during a multi-fraction ICBT course. By analyzing differences in positive lymph 
nodal dose contribution from independent ICBT fractions, we have demonstrated that the 
mean dose to the nodes can differ by up to 1.9 Gy. However, only 20 percent of nodal dose 
varied by greater than 1 Gy. Two tailed Spearman’s rho correlation tests between tandem 
angle and length variations, applicator system location variations in the RL, AP, SI 
directions, total magnitude of applicator system shift, and normalized nodal dose differences 
from independent ICBT fractions were performed. Tandem angle and total system shifts 
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were found to impact distal nodal dose differences while AP/PA and lateral shifts were found 
to impact proximal nodal dose differences. 
5.2.2 Specific Aim 2 
The goal of Specific Aim 2 was to develop and validate deformable image 
registration methods for the use of volumetric summation of bladder and rectum dose from 
ICBT to an external beam planning CT image set. We have successfully developed a method 
to improve DIR accuracy of bladder and rectum between EBRT and ICBT CT images while 
creating a voxel-by-voxel method to validate our results. DIR of the bladder and rectum 
between the EBRT and ICBT image sets were improved by creating a binary image from the 
original CT images using contours delineated by radiation oncologists. Our novel validation 
method uses population CT images to generate a pair of simulated CT images with known 
deformations between them. Validations of our binary method for DIR of bladder and rectum 
have shown mean deformation error for all voxels to be 4.6 mm and 5.6 mm, respectively. 
5.2.3 Specific Aim 3 
This aim was to calculate nodal boost planning margins needed for proton therapy to 
account for interfractional anatomical variations. To determine the required margins, we used 
a fast ray-tracing method to measure differences in WEPL at the target distal and proximal 
edges. We used our method to evaluate interfractional anatomical variations in the common 
iliac and external iliac nodal regions with varying beam angles. We have concluded that 
beam angles are a major determinant of the margins necessary for patients undergoing proton 
therapy. Beams passing through the bowel region, where gas content and weight loss may 
 100 
cause great anatomical variations, require much larger margins than beams entering from 
other directions. 
5.3 TRANSLATING FINDINGS TO THE CLINIC 
The results from each one of the three aims can all be independently used to improve 
current clinical practice. By quantifying the nodal dose variations from independent ICBT 
fractions, radiation oncologists can refer to the results of Specific Aim 1 when deciding how 
much extra dose, if necessary, to prescribe to account for the uncertainties in the second 
ICBT fraction. Also, when conformal radiation therapy is used during external beams and 
spatial total dose information for the bladder and rectum necessary for evaluation, method 
developed in Specific Aim 2 can be used to volumetrically deform ICBT dose onto the 
external beam CT image. Since we also devised a volumetric validation method for our DIR 
algorithm and calculated the mean errors of DIR in the bladder and rectum, physicists and 
radiation oncologists understand the limitations and accuracy of the results when evaluating 
the summed dose. 
For dose delivery to the positive nodes, Specific Aim 3 have determined the margins 
required to ensure target coverage. The margins required to account for interfractional 
anatomical variations can then be added in quadrature with currently used margins 
accounting for other proton uncertainties. Since most patients only require a few fractions of 
nodal boost, treatment with protons for a week should not cause any inconvenience to the 
patient. Also, by using protons, we take advantage its physical properties and spare normal 
tissues beyond the distal edge. For patients already experiencing normal tissue complexities 
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from primary EBRT and ICBT, protons have the potential to spare tissue that would have 
been impossible to avoid with photons. 
5.4 THE END? 
Although we have reached conclusive results in all three aims of the project, the 
knowledge gained from this work will be passed on and be used for future projects. The 
methodologies and tools developed in this project are universal and can be used in many 
anatomical sites. Our deformable image registration validation method is extremely useful at 
a time when dose accumulation using DIR has become much more accessible to the clinic. It 
is robust and can be used on any treatment site and DIR algorithm. Unlike other validation 
methods, it does not require intensive and time consuming landmark identification or 
creating a phantom which might or might not represent the specific patient population and 
deformation. Also, our method of determining interfractional anatomical variations in proton 
therapy using ray-tracing method is not just limited to this project. As long as repeat CT 
images are available for the population of interest, interfractional anatomical variations can 
be quantified for any target and beam angle. In conclusion, the methods created and used in 
this project is just as important as the results. My biggest wish is for future researchers to 
take the methods used in this project and apply it to suit their own specific needs. 
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